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ABSTRACT 
To realize personalized treatment for cancer patients, it is crucial to identify and monitor 
the molecular drivers of tumors. Currently, the molecular analysis of tumors is mostly performed 
on tissue biopsies. However, due to the invasiveness of the procedure, biopsies typically cannot 
be obtained repeatedly during the course of treatment and thus cannot reveal the dynamic 
evolution of tumors on both the genetic and epigenetic levels.  There is a pressing need to 
monitor tumor evolution and to predict the treatment response to guide the clinical decision-
making in the practice of personalized therapy. Circulating tumor cells (CTCs) shed from the 
primary tumor, travel through the blood, and have the potential to cause metastases. As CTCs 
can be frequently sampled from peripheral blood, CTC isolation and analysis hold great potential 
as a biomarker in real-time monitoring of tumor status. 
This work highlights the clinical utility of CTCs for providing prognostic and predictive 
information for specific treatments in cancer patients. First, dynamic changes of PD-L1(+) CTCs 
during radio(chemo)therapy were investigated in NSCLC. The real-time monitoring of PD-L1 
expression in tumor microenvironment is crucial in guiding the therapeutic management of anti-
PD-1/PD-L1 immunotherapy. CTCs were isolated using a nanomaterial based microfluidic 
device, the GO chip. PD-L1 (+) CTCs were detected in 25 out of 36 (69%) samples from 12 
NSCLC patients undergoing radiation or radiochemotherapy. After the initiation of radiation, the 
proportion of PD-L1 (+) CTCs in total CTCs increased significantly (median 4% vs 24%, 
P=0.018). Furthermore, patients who were PD-L1 positive (5% of CTCs stained with PD-L1) at 
	
	 xiii	
baseline had shorter PFS, suggesting the prognostic value of PD-L1 (+) CTCs (6.7 months vs 
14.75 months, P = 0.017) 
Secondly, CTC number and the molecular features of CTCs were monitored at different 
time points during the course of treatment for locally advanced pancreatic patients. The reduction 
of CTC numbers after chemotherapy correlated with shorter progressed free survival (PFS), 
indicating that changes of CTC numbers may be an early indicator for treatment failure (6.5 
months vs 13.5 months, P value= 0.002). Furthermore, in the mRNA profiling of CTCs, the 
expression levels of three genes that have been shown to play a role in drug resistance, BAX, 
CHK1 and EZH2, are associated with poor prognosis, which could act as makers to predict and 
monitor the treatment response. 
Thirdly, this work presents two technical advances of CTC technologies. A highly 
sensitive microfluidic device to capture and release circulating tumor cells from whole blood of 
cancer patients is developed. Graphene oxide is embeded into a thermoresponsive polymer film 
to serve as the first step of an antibody functionalization chemistry. As the temperature decreases 
to around 5 °C, the polymer film dissolves and detaches from the device and captured cells are 
released. Over 90% capture efficiency and release efficiency have been achieved. Released 
CTCs were viable and structurally intact, enabling subsequent analysis such as standard clinical 
cytopathological and genetic testing. Finally, to develop a high throughput CTC isolation 
technology, a herringbone mixer is incorporated into the previously developed GO chip and 
optimized the structure of the herringbone mixer and the channel geometry to maximize the 
	 xiv	
throughput while achieving high capture efficiency (> 80%) and cell viability (> 90%).  The time 
required to process a 1-mL blood sample is reduced to 10 minutes, 6 times faster than in the 
previous design.
1	
	
 
 
 
 
CHAPTER 1 
 
1 Introduction 
 
1.1 Circulating Tumor Cells as 'Liquid Biopsy' 
Distant metastases are the cause of about 90% of deaths of cancer patients[1]. Cancer 
metastasis is an exceedingly complex process, which consists of five sequential steps: (a) 
Detachment from primary tumor, (b) Invasion into blood circulation, (c) Survival in circulation, 
(d) Extravasation into distant organs, (e) Proliferation at the secondary site (Figure 1.1). 
Circulating tumor cells (CTCs) are tumor cells that are shed from the primary tumor and travel 
through the blood to distant anatomic sites. With the potential to initiate metastases, CTCs 
provide a unique opportunity to study the biology of tumor metastasis [2]. Moreover, because 
CTCs can be easily sampled at various time points during the treatment, the isolation and 
analysis of CTCs provides a strategy for monitoring the molecular features of tumor tissues to 
provide predictive and prognostic information for the selection of personalized treatment [3]. 
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Figure 1.1 Tumor metastasis and circulating tumor cells 
 
1.2 Microfluidic Application in Circulating Tumor Cell Isolation  
These circulating tumor cells (CTCs) are incredibly rare and may be present at a 
frequency as low as one CTC per one billion normal blood cells. Engineers have accelerated the 
development of technologies that achieve this goal based on exploiting differences between 
tumor cells and surrounding blood cells such as varying expression patterns of membrane 
proteins or physical characteristics [4]. Collaboration with biologists and clinicians has allowed 
additional analysis and will lead to the use of these rare cells to their full potential in the fight 
against cancer.   There have been several macroscale attempts to isolate CTCs based on how they 
differ from the surrounding blood cells, including the FDA approved CellSearch system [5] and 
Isolation by Size of Tumor cells [ISET]) platform. However, these technologies suffered from 
drawbacks such as the low yield and sensitivity, fixation requirements, and high white blood cell 
(WBC) contamination [6]-[9]. The successful sensitive selection of viable cells was greatly 
advanced through the introduction of the CTC Chip [10], a microfluidic technology that also 
marked the entry of engineers into this field. Microfluidic systems offer the advantages of low 
footprint, small sample volume, low reagent usage, pre-established inexpensive rapid 
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prototyping methods, diffusion dominated transport, and a length scale on par with cellular 
systems [11], making them a natural fit for use in CTC research. 
Engineers continue to play an integral role in the further optimization of CTC isolation, 
aiming for increased sample throughput, target cell sensitivity and purity, and viability to 
ultimately allow the complete interrogation of this useful cell population. As the interest and 
publication of CTC technologies continues to increase [12], engineers working with teams of 
clinical collaborators are using varied principles and techniques within microfluidic capture 
devices (Figure 1.2). Exploitation of expression of cell surface markers, size variation, and other 
differences have allowed some success and will be covered below, in addition to applications of 
such devices and potential future directions and challenges.  
	 4	
 
Figure 1.2 Circulating tumor cell (CTC) isolation technologies. 
A brief history of CTC isolation technologies beginning with the first FDA approved technique, 
CellSearch. Microfluidics was introduced in 2007 with the CTC Chip. Subsequent developments 
have occurred in the areas of immunocapture and size based isolation [4].  
 
1.2.1 Immunocapture of CTCs: a biomarker dependent but highly 
specific technique 
Immunocapture, which is used by CellSearch, the CTC Chip, and many subsequent 
devices (Figure 1.3), takes advantage of the variety in proteins expressed on the cell membrane 
of CTCs but not of WBCs, such as the epithelial cellular adhesion molecule (EpCAM), that may 
be targeted by antibodies against such moieties that are tethered to a surface or feature. The CTC 
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Chip consisted of 780,000 microposts etched in silicon which were then functionalized with 
antibodies against EpCAM (anti-EpCAM) and was validated with blood samples from lung, 
prostate, pancreatic, breast and colon cancer patients. This device viably detected cells in a 
greater percentage of patients and at lower levels and with higher purity than shown by the 
CellSearch system. This enabled the molecular characterization of CTCs demonstrating tumor 
specific genetic alterations present in CTCs [13]. However the need for higher throughput, 
sensitivity, and the ability to further characterize and study these cells beyond enumeration 
prompted further developments. 
 
Figure 1.3 Immunocapture methods for microfluidic circulating tumor cell (CTC) isolation. 
Examples of a number of techniques used to improve metrics such as sensitivity, purity, 
throughput, and ease of use or fabrication of immunocapture devices include the use of silicon 
microposts, thermoplastics, micromixers, radial flow, nanomaterials, and immunomagnetic 
separation [4]. 
 
Computational fluid dynamics simulation assisted the redesign of micropost shape and 
layout in the geometrically enhanced differential immunocapture (GEDI) octagonal micropost 
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device that has been functionalized with anti-prostate specific membrane antigen (PSMA) [14] or 
anti-HER2 to target breast and gastric cancers as validated with patient samples [15]. In contrast 
to micropost devices, high aspect ratio serpentine thermoplastic microchannels maximize 
collisions between anti-EpCAM functionalized channel walls and CTCs. By using 51 parallel 
microchannels embossed in polymethylmethacrylate (PMMA), the high throughput 
microsampling unit (HTMSU) enabled efficient sample processing followed by immediate 
enumeration of captured CTCs via platinum conductivity sensor [16]. Modifications to the inlet 
and outlet design as well as the substrate material, now cyclic olefin copolymer (COC), yielded 
the high-throughput (HT) CTC device [17]. In the NanoVelcro system, cells were released using 
a thermoresponsive polymer following capture on high surface area silicon nanopillars within a 
microfluidic chip capped with a chaotic micromixer to increase contact between cells and 
antibody functionalized surfaces [18]. 
The chaotic micromixer chamber was first used in the Herringbone (HB) Chip, a follow 
up to the CTC Chip [19]. Consisting of several parallel functionalized channels in 
polydimethylsiloxane (PDMS), this device detected CTCs in 14/15 prostate cancer patient 
samples. Subsequently, the herringbone chamber was integrated with a degradable layer-by-layer 
(LbL) assembled coating consisting of gelatin and functionalized nanoparticles to increase 
antibody presentation and allow both single cell and bulk release [20]. Utility was verified with 
breast and lung patient samples. 
Besides multiplexing to increase throughput, a radial flow strategy was used to increase 
flow rate while decreasing the linear velocity and therefore shear stress exerted on the cells. This 
OncoBean Chip [20] also featured a redesigned functionalized micropost structure to minimize 
flow separation, increasing the area on the post utilized in capture. 
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In contrast to the aforementioned 3D features, the GO Chip incorporated the 
nanomaterial graphene oxide (GO) for the first time to capture CTCs. GO allowed highly 
specific and selective capture of CTCs on an effectively 2D surface through a functionalization 
chemistry that presented the antibody on a high surface area material [21]. The device was 
verified by capturing CTCs from breast, lung, and pancreatic patient samples. 
An alternative to a functionalized surface is magnetic beads functionalized with 
antibodies that adhere to cells, which may then be separated using an external magnet. In the 
CTC-iChip, cells in blood samples were magnetically labeled in a preprocessing step, followed 
by the initial separation of small cells through deterministic lateral displacement (DLD) and 
alignment by inertial focusing (to be further discussed in ‘Size based capture’) and ultimate 
separation through magnetic sorting of the prelabeled cells [23]. In ‘positive selection’ mode, 
magnetic beads were functionalized to target CTCs, while in ‘negative selection’ mode, magnetic 
beads were functionalized against WBC markers, allowing those cells to be removed, leaving 
any remaining cells, including EpCAM negative cells, for further analysis. That the cells are not 
bound to a surface facilitated further study. 
Other immunomagnetic systems prioritize ease-of-use. The VerIFAST (Immiscible 
Filtration Assisted by Surface Tension) system [22] processed small volumes of peripheral 
mononuclear blood cells that have been prelabeled with functionalized magnetic beads. Using a 
handheld magnet, labeled cells are then dragged through successive chambers machined in 
polystyrene that are gated by oil trapezoids to separate CTCs from non-target cells and guide 
them into a staining well. This allowed for analysis of both blood and mini-bronchoalveolar 
lavage samples from lung cancer patients. 
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Immunoaffinity microfluidic separation has turned to a variety of materials and structures 
to improve in areas where isolation technologies are still lacking. Each device balances added 
functionality of various features and materials with the associated necessary expertise or 
increased fabrication logistics and costs. Downstream analysis is hindered when cells remain 
attached to the capture substrate, although the nascent field of cell release and immunomagnetic 
capture may counter this. A commonality among these devices is that a specific population is 
assumed to be the entirety of the target CTC population based on the choice of capture antibody, 
missing cells in transformations such as the epithelial to mesenchymal transition (EMT). Some 
of these drawbacks have been addressed through the incorporation of nanomaterials [23]. 
Another category of CTC isolation techniques prioritizes label free capture and often has the 
added advantage of high throughput, although this strategy has its own drawbacks.  
1.2.2 Size based capture 
CTCs also differ from blood cells in size and deformability, offering molecular marker-
independent, high-throughput, and inexpensive options for isolation (Figure 1.4). CTCs are 
generally larger and stiffer than WBCs, leading to the early use of commercial filters [24], [25]. 
To solve problems with earlier filters including fixation requirements, non-uniform pore sizes, 
and low pore density, the separable bilayer (SB) microfilter was microfabricated by etching 
parylene polymer via reactive ion etching to precisely control pore sizes and density [26]. 
Parylene is ideal for this application because it is mechanically strong while still malleable, with 
good biocompatibility and low membrane fouling. The bilayer design consisted of a bottom layer 
with 8 µm pores and a top layer with 40 µm pores, trapping CTCs between the two layers that 
could be separated easily, leaving CTCs accessible. A flexible micro spring array (FMSA) was 
designed as a high-porosity filter [27] capable of processing 7.5 mL whole blood without 
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clogging while still preserving viability. CTCs were detected in 76% of clinical samples from 
breast, colorectal, and lung cancer patients. Microclusters and multinucleated CTCs were 
enriched from patients from all three cancers. 
 
Figure 1.4 Size based technologies for circulating tumor cell (CTC) separation.  
On the basis of differences in size between CTCs and white blood cells, microfilters and inertial 
sorting techniques have been incorporated into microfluidic CTC isolation [4]. 
 
An alternative approach to separation exploited unique properties of particles moving in 
microchannels. Under laminar flow, deterministic lateral displacement (DLD) within an array of 
microposts has been used to separate particles of different sizes [28]. Depending on the geometry 
of the microarrays, particles above and below a certain size follow different and predetermined 
migration paths. The CTC-iChip (also mentioned in the Immunocapture section) utilized DLD to 
first separate nucleated cells (CTCs and WBCs) from red blood cells (RBCs) using an array of 
microposts with 32-µm gaps [31]. When flowing through the device, small cells like RBCs 
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remained along their original streamlines, whereas larger cells like CTCs and most WBCs were 
fully deflected into the coincident running buffer stream by the end of the array. 
Other separation approaches exploited inertial forces. Within microchannels, particles of 
different sizes can migrate across streamlines to focus at different positions due to the shear 
induced lift force and the wall induced lift force. In vortex technology, cells of various sizes are 
aligned by size in different streamlines in straight channels by inertial focusing followed by 
multiple expansion-contraction reservoirs to create laminar microvortices that can trap large cells 
within reservoirs [29]. As cells entered the expanding regions, wall lift forces were diminished 
and cells mainly experienced lateral lift forces, which are proportional to the cell volume. The 
larger lift forces on CTCs pulled them into the vortices while other blood cells experiencing 
smaller forces passed through the vortex and remained in the main stream. 
Curvature in microchannels causes particles to experience an additional lateral Dean drag 
force because fluids in curved channels develop a secondary lateral flow. The combination of the 
inertial lift force and the Dean force leads to particle migration which can result in high 
resolution separation. Single spiral, double spiral, cascaded spiral, and slanted spiral structures 
have been designed and optimized to maximize separation efficiency for various parameters 
including channel length, height, width, radius of curvature, and flow rate [29]-[33] . Generally, 
near the outlet of spiral devices, larger CTCs focus near the inner wall due to the combination of 
the inertial lift force and the Dean drag force. To this end, Hou et al. designed a multiplexed 
spiral device that detected CTCs in clinical samples from breast and lung cancer patients [34]. 
CTC enrichment by size offers a fast, inexpensive, and label-free way to harvest CTCs. 
However, as there is a wide range of CTCs sizes, sized based separation often suffers from low 
purity and the risk of losing smaller CTCs. Additionally, size based separation often requires 
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preprocessing of blood, like RBCs removal and further, dilution or runs the risk of device 
clogging. To date, size based technologies have shown proof-of-concept clinical validation but 
have not been applied in large scale clinical or biological investigation. 
Other separation methods based on physical properties include the interplay of 
dielectrophoresis (DEP) forces and inertial forces in microfluidic devices to lead to different 
patterns of cell migration to viably separate cells [35]. Similarly, acoustophoresis causes particles 
within the fluid to move toward regions with minimal acoustic radiation forces in distinct 
migration patterns [36], [37]. Although promising, approaches like DEP and acoustophoresis 
have the disadvantages of low throughput, low sensitivity and purity, and additional required 
steps like RBC lysis and may require further clinical validation. 
1.3 The biology of circulating tumor cells 
1.3.1 Epithelial–mesenchymal transition 
Occurrence of the epithelial-to-mesenchymal transition (EMT) process is observed in 
various types of human cancer and may play an important role in tumor metastasis and resistance 
to standard treatment [38]. During EMT, epithelial cells lose cell-cell contacts and their apical–
basal polarity and become spindle-shaped mesenchymal cells. These changes lead to the 
detachment of tumor cells from the extracellular matrix (ECM) and increase their ability to 
invade into the surrounding stroma and intravasate into the bloodstream, initiating the metastatic 
process [39].  
The functions of EMT may vary greatly depending on the cancer types. In squamous cell 
carcinoma, EMT driven by the activation of Akt is associated with enhanced motility and 
invasiveness [40]. In pancreatic cancer, EMT induces chemoresistance but has little effect on 
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increasing invasiveness or metastasis [41]. In breast cancer, Mani et al. observed that after the 
induction of EMT, cells acquire stem cell properties such as self-renewal [42].  
At the molecular level, the expressions of many epithelial junction proteins such as E-
Cadherin and α-catenin are down-regulated or lost during EMT [43], [44]. Furthermore, 
intermediate filaments are rearranged, typically switching from cytokeratins to vimentin. EMT 
can be induced by both intrinsic and extrinsic factors including multiple transcription factors 
(e.g. Snail, Twist, Slug, ZEB1, FOXC2), growth factors (e.g. epidermal growth factor (EGF), 
transforming growth factor β (TGF-β)), and small non-coding RNAs (micro-RNAs, e.g. miR-200 
or miR-155). Several signaling pathways play an important role during EMT, e.g. Ras/MAPK, 
PI3 K/Akt/GSK, and Wnt/β-catenin.  
The loss of epithelial markers (e.g. E-Cadherin), the up-regulation of mesenchymal 
markers (e.g. Vimentin and N-Cadherin) and the activation of EMT regulator (e.g. Snail, Twist, 
Slug and ZEB1) have been use to characterize EMT process in cancer cells [38]. Molecular 
analysis of tumor specimens revealed that the expression of EMT markers have emerged as 
independent prognostic markers in various cancer types such as breast cancer [45], lung cancer 
[46], gastric cancer [45], and oral squamous cell carcinoma [50].  
The analysis of EMT markers in CTCs is another exciting research area. CTCs 
undergoing EMT may not be captured by many CTC isolation assays relying on the expression 
of epithelial marker like EpCAM. This could be resolved by applying a cocktail of antibodies 
targeting both epithelial and mesenchymal markers or by using physical property based 
separation. These approaches identified a population of mesenchymal like CTCs in various 
cancer types such as breast, lung, and prostate cancer [47]-[50]. In these studies, the expression 
of EMT markers in CTCs was found to be heterogeneous and CTCs were classified into different 
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subgroups using EMT markers, including epithelial CTCs, intermediate CTCs and mesenchymal 
CTCs.  
The expression of EMT markers in CTCs could undergo dynamic changes throughout the 
treatment course.  Yu et al studied the changes of EMT characteristics of CTCs after 
chemotherapy using RNA–in situ hybridization (ISH) assay among breast cancer patients [51]. 
Using a panel of epithelial and mesenchymal genes they identified a spectrum of CTCs ranging 
from exclusively epithelial to intermediate and exclusively mesenchymal. The comparison of 
CTC features in samples before and after chemotherapy showed that the increase of 
mesenchymal like CTCs after treatment were associated with disease progression. After 
analyzing CTCs by RNA sequencing, the authors reported that 170 transcripts were enriched in 
CTCs captured at a mesenchymal predominant time point, and suggested that aberrant 
expression of FOXC1, along with TGF-β activation, may be a contributor to EMT in human 
breast cancer. This result suggested that the expression of EMT markers in CTCs could be 
used as a potential biomarker of therapeutic resistance and cancer progression. Furthermore, 
studying the mechanism of EMT regulation in CTCs could bring insights into developing 
potential drug targets for cancer treatment. 
1.3.2 Circulating tumor microemboli 
Circulating tumor microemboli (CTM), or CTC cluster, are clusters formed by more than 
two CTCs. In addition, CTCs have been observed to associate with leukocytes, platelets, and 
stromal cells such as fibroblasts to form clusters [52], [53]. CTM have been detected by various 
CTC technologies in different cancer types such as breast, lung, prostate, and pancreatic cancer 
[54]-[56]. The presence of CTM is associated with poor prognosis in pancreatic and small cell 
lung cancer [57], [58]. Change et al demonstrated that in pancreatic cancer patients CTM were 
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abundantly present in 81% of patients and that the number of CTM is an independent prognostic 
marker of overall survival (OS) and progression free survival (PFS) [57].  
CTC clusters have been proposed to have higher metastatic potential compared to single 
CTCs [56]. Possible explanations for this phenomenon include resistance to anoikis, presence of 
stromal cells providing a permissive microenvironment and presence of blood cells for immune 
escape [59]. 
Cells generally undergo apoptosis after they lose contact with neighboring cells or with 
extracellular matrix (ECM), in a process named ‘anoikis’. The ability to resist anoikis is essential 
for CTCs to initiate cancer metastases. The avoidance of anoikis can be attributed to the cell 
junctions preserved by CTMs [56]. In metastatic breast cancer, the expression level of cell–cell 
junction marker plakoglobin in CTM is found to have a 200-fold increase than that of single 
CTC [56]. Plakoglobin knockdown triggered the dissociation of CTM and resulted in a reduced 
number of lung metastases in mouse models. Therefore, while epithelial tumor cells that are shed 
into the blood circulation and lose cell-cell contact generally undergo anoikis, CTMs still 
preserve some level of cell junction and could survive in the circulation.  
Several blood cell types, such as platelets, leukocytes, and myeloid-derived suppressor 
cells (MDSC), have been proposed to shield tumor cells escape from immune surveillance, 
facilitating the formation of distant metastases [60]-[62]. Additionally, platelets adhere to CTCs 
has been shown to induce EMT activation in tumor cells and promote metastasis. Bastid et al 
suggested that CTCs can enter the vasculature as epithelial tumor cells and upon stimulation by 
platelets-derived TGF-β can change into mesenchymal tumor cells [63]. This work showed that 
the co-culture with platelets resulted in an increased number of metastatic foci generated by 
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tumor cells injected into the tail-vein of the examined mice. In contrast, selective knock-out of 
TGF-β in platelets and megakaryocytes led to the reduction of metastatic events.  
The effect of stromal cell presence in CTM has been studied in mouse models [64]. It is 
demonstrated that CTCs can attach to cancer-associated fibroblast (CAF), which results in higher 
viability of cancer cells in circulation and the increased early growth of metastatic colonies in 
lung. By bringing its own soil (stromal cells), tumor cells can gain a favorable traveling and 
seeding niche to form metastatic colonies.  
1.4 Clinical use of CTCs — non–small-cell lung cancer (NSCLC) 
Lung cancer is the leading cause of cancer-related death in US and worldwide, with non–
small-cell lung cancer (NSCLC) accounting for more than 80% of those cases[65]. CTC analysis 
provides opportunities in early diagnosis, prognosis, evaluation of curative efficacy, and 
molecular analysis of lung cancer for targeted therapies [66], [67]. 
1.4.1 CTCs as prognostic and predictive markers  
Many studies have shown that the presence of CTCs is associated with shorter PFS or OS 
time using different technologies and thresholds. Krebs et al used CellSearch Assay to isolate 
CTCs from 101 untreated stage III/IV NSCLC patients. Stage IV patients were found to have 
higher CTC counts than stage III patients. Patients with >5 CTCs at baseline had shorter PFS 
(2.4 vs. 6.8 months) and OS (4.3 vs. 8.1 months) than those with <5 CTCs at baseline (P<0.001).  
Additionally, CTCs were measured after one cycle of chemotherapy, and the reductions of CTCs 
after chemotherapy were associated with improved PFS (5.4 vs. 1.9 months; P < 0.001) and OS 
(8.3 vs. 3.3 months; P < 0.009). Using another CTC isolation technology ISET, Hofman et al 
identified CTCs in 49%(102 out of 208) of patients by morphological examination [68]. The 
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presence of 50 or more CTCs was associated with worse disease free survival (DFS) for both 
early-stage I + II- and later-stage III + IV-resectable NSCLCs (P = 0.05, and P < 0.0001, 
respectively).  
To compare these two commercialized CTC isolation methods, Hofman et al conducted 
another study isolating CTCs by the CellSearch Assay™ and by ISET from 210 patients 
undergoing radical surgery for NSCLC [68]. CTCs were detected in 104 of 210 (50%) and 82 of 
210 (39%) patients using ISET and CellSearch, respectively. Patients with CTCs detected by 
CellSearch alone or by ISET alone had worse DFS than patients without CTCs (p < 0.0001). 
However, no correlation between the presence of CTCs and disease stage, or other 
clinicopathologic parameters was observed in this study.  
CTCs are typically isolated from peripheral blood of cancer patients. To increase the 
likelihood of CTC enrichment, Hashimoto et al. sampled pulmonary vein (PV) blood to isolate 
CTCs from in patients undergoing surgery. CTCs were more frequently observed in PV blood 
than in peripheral blood (73.3% vs 6.7%). Interestingly, CTC number increased significantly 
after surgical manipulation and the increase of CTCs in PV blood was significantly associated 
with lymphatic invasion (P = 0.043). Another phenomenon observed in PV blood by Funaki et al 
was the presence of CTC clusters (present in 33% of the patients) . The existence of CTC 
clusters was correlated to worse disease-free survival rate (P<0.001). This is consistent with 
other reports about the prognostic value of CTC clusters [57],	[58],	[69]. 
The predictive value of CTCs for assessing treatment response was examined by a 
study investigating the correlation between CTC enumeration and radiographic appearance 
[70]. Treatment response to chemotherapy agents is generally assessed by comparing baseline 
and post-treatment positron emission tomographic (PET) imaging and computed tomographic 
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(CT) scans. Punnoose et al correlated the changes in CTC levels with CT scans, which is 
evaluated via Response Evaluation Criteria in Solid Tumors (RECIST), and 
fluorodeoxyglucose-PET (FDG-PET) imaging. The authors showed that patients with partial or 
complete responses tend to have higher baseline CTC counts than patients with stable disease 
or progressive disease. Meanwhile, the reductions of CTC counts after chemotherapy were 
associated with FDG-PET and RECIST response (P = 0.014 and P = 0.019) and longer PFS (P = 
0.050), suggesting that monitoring of the changes in CTC numbers could be used as an early 
indication of response. Similarly, additional studies showed that the decreases in CTC number 
were associated with shorter PFS and OS, indicating that CTCs could be used as surrogate 
biomarker for evaluating the effectiveness of chemotherapy [71], [72]. 
1.4.2 CTCs as a biomarker for early detection and diagnosis  
Because of the low cost and the minimal invasiveness of CTC isolation, CTCs have the 
potential to offer a cost efficient way to screen patients with a high risk of lung cancer. Ilie et al 
examined the presence of CTCs among 168 patients with Chronic obstructive pulmonary disease 
(COPD)[73]. Within 1 to 4 years after CTC detection, the 5 CTC-positive patients were detected 
with lung nodules by CT scan, which led to prompt surgical resection and the diagnosis of early-
stage lung cancer. This result indicated that CTCs could be used to monitor COPD patients for 
the early detection of lung cancer. 
To study the diagnostic value of CTCs, Fiorelli et al conducted a study using CTCs to 
differentiate benign from malignant lung lesions [74]. Malignant circulating cells (their term for 
CTCs) were detected in 54 of 60 (90%) malignant patients and in 1 of 17 (5%) benign patients 
whereas benign circulating cells were detected in 1 of 60 (1%) malignant patients and in 15 of 17 
(88%) benign patients. CTCs shared morphological features similar to those of the corresponding 
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primary tumor and lead to the same histologic diagnosis in 72% cases. Although promising, the 
early detection and diagnosis of CTCs still need to be validated in large-scale clinical studies. 
However, the low abundance of CTCs present in early stage cancer may hinder the detection 
rate, thus more sensitive technologies are needed to allow the advances in this area.  
1.4.3 CTCs as a biomarker for early detection and diagnosis markers 
Due to the low cost and the minimal invasiveness of CTC isolation, CTCs have the 
potential to offer a cost efficient way to screen patients with high risk of lung cancer. Ilie et al 
examined the presence of CTCs among 168 patients with Chronic obstructive pulmonary disease 
(COPD) [73]. Within 1 to 4 years after CTC detection, the 5 CTC-positive patients were detected 
with lung nodules by CT scan, which leads to prompt surgical resection and the diagnosis of 
early-stage lung cancer. This result indicated that CTCs could be used to monitor in COPD 
patients for the early detection of lung cancer. 
To study the diagnostic value of CTCs, Fiorelli et al conducted a study to use CTCs to 
differentiate benign from malignant lung lesions [74]. Malignant circulating cells or CTCs were 
detected in 54 of 60 (90%) malignant patients and in 1 of 17 (5%) benign patients whereas 
benign circulating cells CTCs were detected in 1 of 60 (1%) malignant patients and in 15 of 17 
(88%) benign patients. CTCs shared similar morphological features and lead to the same 
histologic diagnosis of the corresponding primary tumor in 72% cases. Although promising, the 
early detection and diagnosis of CTCs still need to be validated in large scale clinical studies. 
Besides, the low abundance of CTCs present in early stage cancer may hinder the detection rate 
and thus more sensitive technologies are needed to allow the advances in this area.  
1.4.4 CTCs used for the molecular analysis in targeted therapy 
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Nearly two thirds of the patients with advanced lung cancer acquire at least one of the 
recognized “driver mutations”, which are specific gene mutations that are involved in driving the 
development of lung cancer [75]. The most common driver mutations are mutations in epidermal 
growth factor receptor (EGFR) and the rearrangement of ALK gene. Other genomic aberrations 
such as HER2, KRAS, PIK3CA, AKT and BRAF mutation and amplification have also been 
extensively studied. The development of targeted agents, such as EGFR inhibitors and ALK 
inhibitors has changed paradigms of management of patients with these mutations. Biopsies may 
not provide enough samples for mutation analysis at the time of diagnosis and cannot be sampled 
frequently during treatment. Thus CTCs may provide an additional way of assessing and 
monitoring the tumor genotypes.  
Maheswaran et al conducted the first study to monitor EGFR mutations in CTCs isolated 
by CTC chip during targeted therapy among metastatic NSCLC patients [76]. EGFR mutation 
was detected in CTCs from 11 of 12 patients (92%). Furthermore, the emergence of a treatment 
resistance mutation, T790M, was found in CTCs samples during the treatment and was 
associated with tumor progression. These findings indicated that CTCs could monitor the 
mutation status of tumor tissue and might predict the treatment outcomes. Using an RT-PCR 
assay, Breitenbuecher et al. were able to detect EGFR mutations in CTCs among all 8 EGFR 
mutant patients [77]. After following the patients through the treatment, they demonstrated that 
patients without EGFR-mutant CTCs during treatment were more likely to respond to therapy 
than those with persisting EGFR-mutant CTCs. 
Several other studies have investigated the detection of ALK rearrangement in CTCs. 
Pailler et al examined the ALK status in CTCs via a filtration enrichment technique and filter-
adapted fluorescent in situ hybridization (FA-FISH) [78]. All ALK-positive patients had four or 
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more ALK-rearranged CTCs per 1 mL of blood whereas no or one ALK-rearranged CTC was 
detected in ALK-negative patients. Furthermore, they detected the changes of ALK-rearranged 
CTC levels in patients being treated with a tyrosine kinase inhibitor of ALK, crizotinib. Similar 
results are reported in a study using a microfluidic platform, NanoVelcro chip[79]. The ALK 
status detected in CTCs accurately matched the status of tumor samples when applying a cutoff 
of 3 ALK-rearranged CTCs. Overall, these studies using different isolation technologies 
suggested that CTCs could be used for ALK-gene status pre-screening on a routine basis for 
patients with lung cancer and open new opportunities for real-time monitoring of targeted 
therapies. 
1.5 Clinical use of CTCs — Pancreatic cancer 
1.5.1 CTCs as a biomarker for diagnosis and staging  
Pancreatic cancer is a very aggressive cancer type; the five year survival rate is only 8% 
[80].  It is usually diagnosed at an advanced stage and is resistant to treatment. Even when 
patients are diagnosed with small primary tumors (<2 cm) and have no clinical evidence of 
metastatic disease, 5-year survival after surgery is less than 18% because of metastatic disease 
[81]. More interestingly, some patients undergoing surgery for chronic pancreatitis will develop 
disseminated pancreatic adenocarcinoma (PDAC), although only precancerous lesions of 
pancreas, but no tumors, are found locally [82]. These observations suggest that tumor 
dissemination may occur before the formation of large primary tumors or the diagnosis of the 
tumor.  
Rhim et al showed that circulating pancreatic cells were detected in liver before the 
formation of pancreatic tumor in a lineage-labeled genetic model of pancreatic cancer, 
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suggesting that metastatic seeding could occur before tumor formation[83]. To validate this 
finding in a clinical setting, Rhim et al reported that more than 3 circulating pancreas epithelial 
cells/mL were detected via GEDI chip in 7 of 21 (33%) patients with cystic lesions and no 
clinical diagnosis of cancer [84]. This result indicates that circulating pancreas epithelial cells 
could be useful as a biomarker for risk assessment in patients with high risk of pancreatic cancer 
or even for early detection of pancreatic cancer. 
Clinical staging of pancreatic cancer based on multi-section CT or MRI imaging may not 
be sensitive enough to detect small-volume metastatic lesion, which causes under-staging. 
Approximately 80% of patients who undergo successful surgery will experience metastatic 
recurrence, indicating that distant metastases may be present at the time of surgery [85]. In these 
cases, surgery may not be the proper initial treatment. Thus a biomarker that could improve the 
accuracy of staging is needed to assist the selection of frontline therapy. Ankeny et al processed 
blood samples from 100 pancreatic cancer patients using the microfluidic NanoVelcro CTC chip 
and demonstrated that a cut off of ≥  3 CTC in 4 ml blood could discriminate between 
local/regional and metastatic disease [86]. In addition, they performed mutational analysis of 
KRAS codon 12 in CTCs and achieved 100% concordance of KRAS mutation subtype between 
CTCs and primary tumor tissue in five patients tested. This study showed that CTCs could be 
used as an adjunct biomarker for molecular diagnosis and staging of PDAC at the time of disease 
presentation.  
1.5.2 CTCs as a biomarker for prognosis  
Han et al conducted a meta-analysis to evaluate the prognostic value of CTCs in 
pancreatic cancer [87]. In this meta- analysis, nine cohort studies were included with a total of 
623 pancreatic cancer patients consisting of 268 CTC-positive patients and 355 CTC- negative 
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patients. Four studies used CellSearch technology to enumerate CTCs while the other four 
studies use RT-PCR to detect the expression of CTC specific genes. The meta-analysis revealed 
that patients in the CTC-positive group were significantly associated with poor progression-free 
survival (PFS) and overall survival (OS) (P<0.001, P<0.001) [87].  
Furthermore, as most cancer deaths are associated with metastases and CTCs can 
potentially initiate metastatic spread, CTCs can be used to identify specific genes to serve as 
prognostic markers in patients with pancreatic cancer. Sergeant et al studied the gene-expression 
profiles of CTCs isolated by FACS-based negative depletion among patients who underwent 
surgery for PDAC [92]. Based gene expression analysis and pathway analysis, they developed a 
CTC gene signature consisting of TGF-β1 involved in the p38 MAPK pathway and 9 other genes 
associated with both p38 MAPK signaling and cell motility. They validated the prognostic value 
of this CTC gene signature in 78 primary tumor tissue samples and revealed that high co-
expression of TGF-β1 and the cell motility panel in primary pancreatic cancer was an 
independent predictor of disease-free (DFS) and overall survival (OS) (p=0.041, p=0.047). 
Recently, the prognostic value of CTM in pancreatic cancer was investigated by Chang et 
al [57]. They detected CTM in 81% (51 of 63) of patients with mean (SD) 29.7 (1101.4). With a 
cutoff of 30 CTMs per 2 ml, patients are categorized into favorable and unfavorable CTM group. 
Compared to the favorable CTM group, the unfavorable CTM group had much shorter PFS (2.7 
vs 12.1 months; P <0.0001) and OS (6.4 vs 19.8 months; P <0.0001).  
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CHAPTER 2 
 
2 Monitoring Dynamic Changes of PD-L1 (+) CTCs in Non-
Small Cell Lung Cancer During Radio(chemo)therapy 
	
2.1 Abstract 
The development of immune checkpoint inhibitors such as anti-PD-1/PD-L1 marks a new 
era in treating cancer with immunotherapies. Preclinical studies demonstrated that radiation up-
regulates PD-L1 expression in tumor cells, which provides the primary rationale for combining 
PD-1/PD-L1 inhibitors with radiation. These results haven’t been validated among non-small cell 
lung cancer (NSCLC) patients because it is difficult to obtain serial biopsy samples to monitor 
the PD-L1 expression in NSCLC. Measuring the PD-L1 expression of circulating tumor cells 
(CTCs), which could be sampled repeatedly with minimal invasiveness, enables the real-time 
monitoring of immune activation in tumor. Using a nanomaterial based microfluidic device (the 
GO chip), we obtained serial blood samples from 12 non-metastatic NSCLC patients undergoing 
radiation or radiochemotherapy. CTCs were detected in all 36 samples with the average of 20.8 
CTCs/ml (range 4-72) and PD-L1 (+) CTCs were detected in 24/36 samples (66.7%) with an 
average number of 4.7/ml (range 0-43). After the initiation of radiation, the proportion of PD-L1 
(+) CTCs among total CTCs increased significantly (median 0.7% vs 24.7%, P < 0.01), 
indicating the upregulation of PD-L1 expression in tumor cells during radiation. In addition, 
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patients who were PD-L1 positive (5% of CTCs stained positive for PD-L1) at baseline had 
shorter PFS time (6.7 months vs 14.75 months, P < 0.05), while the total CTC number is not 
associated with poor prognosis. The mRNA levels of PD-L1 were significantly higher in the 
samples from patients with poor prognosis (PFS < 9 months) than in those from good prognosis 
patients (PFS > 9 months). Therefore, PD-L1 expression in CTCs may have prognostic value and 
may serve as a biomarker to monitor tumor immunity among non-metastatic NSCLC patients. 
2.2 Introduction 
Lung cancer is the leading cause of cancer-related death in the US and worldwide, with 
non–small cell lung cancer (NSCLC) accounting for over 80% of those cases [65], [80].  Non-
metastatic NSCLC patients who are medically inoperable or unresectable are generally offered 
radiotherapy with or without concurrent chemotherapy which yields 5-year overall survival rates 
ranging from 10–35% [88]-[90]. New treatment options are urgently needed for these patients. 
Recent development in checkpoint immunotherapy draws the beginning of a new era in 
NSCLC treatment. Programmed death 1 (PD-1) receptor and its ligand (PD-L1) are key 
checkpoint molecules for regulating antitumor immune responses [91]. The binding of PD-L1 to 
PD-1 can inhibit T cell function and proliferation and result in immune tolerance. As PD-L1 
expression has been found in various tumors including NSCLC [92], the blockage of PD-1/PD-
L1 has emerged as a new therapeutic approach that can restore the antitumor immunity. 
Exciting results from clinical trials of PD-1/PD-L1 inhibitors have shown improved 
overall survival with low toxicity among NSCLC patients [93]-[95]. Based on data from the 
recent phase 3 trial, the PD-1 inhibitor pembrolizumab was approved by the US Food and Drug 
Administration (FDA) for the first-line treatment of metastatic NSCLC whose tumors have 50 
percent or more PD-L1 expression with no EGFR or ALK genomic tumor aberration [96]. To 
	
	 25	
further improve the response rate and duration and to extend the benefit to additional patients, 
the idea of combining anti–PD-1/PD-L1 therapies with radiation or radiochemotherapy has been 
proposed and tested in clinical trials among non-metastatic NSCLC patients [97]-[99]. Growing 
evidence demonstrates that radiation can elicit adaptive immune response, but this immunogenic 
effect of radiation could be undermined by the upregulation of PD-L1 in tumor 
microenvironment. This provides the primary rationale for combining PD-1/PD-L1 inhibitors 
with radiation [100], [101]. However, the upregulation of PD-L1 expression during radiation has 
not been validated among NSCLC patients because it is difficult to obtain serial biopsy samples 
to monitor the PD-L1 expression in solid tumors due to the invasiveness of biopsies. 
Alternately, isolation of circulating tumor cells (CTCs), as a mean of liquid biopsy, 
provides a minimally invasive method to repeatedly sample tumor cells from the patient’s blood  
and to monitor PDL-1 expression on tumor cells over time. The potential of CTCs as a 
prognostic and surrogate biomarker for NSCLC has been investigated using the FDA approved 
CellSearch System [67], [70], [72], [102]. However, due to the low detection sensitivity of this 
assay, the CellSearch system has been reported to undercount CTCs and has a limited ability to 
detect CTCs in non-metastatic NSCLC patients, which largely limits its clinical utility [71]. 
Microfluidic based CTC isolation technologies have emerged as an approach to capture 
CTCs with high sensitivity and have demonstrated the capacity to characterize the molecular 
traits of tumors, such as EGFR mutations [4], [13], [22], [67], [79]. Previously we developed a 
nanomaterial based microfluidic platform for CTC isolation, the GO chip, which consists of a 
microfluidic chamber and a substrate coated with graphene oxide (GO) nanosheets where the 
antibodies are tethered [21]. This technology takes advantage of the increased surface area 
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afforded by graphene oxide to achieve higher antibody coating density, and thus improved 
sensitivity for CTC capture.  
In this study, to investigate whether radiation therapy can increase PD-L1 expression in 
CTCs, we monitored the dynamic changes of PD-L1 expression in CTCs via the GO chip among 
12 non-metastatic NSCLC patients who received radiation alone or with concurrent 
chemotherapy (Figure 2.1). Furthermore, we evaluated whether PD-L1 (+) CTC counts and PD-
L1 mRNA expression level have correlation with disease progression. 
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Figure 2.1 An	overview	of	this	study 
An overview of this study, with sample collection and circulating tumor cell (CTC) isolation 
before treatment, during treatment and months after treatment (follow up). The GO chip 
configuration and work mechanism is also shown by the schematic representations of  CTC 
isolation within the microfluidic chamber and of antibody conjugation chemistry. 
2.3 Materials and Methods 
2.3.1 GO Chip production and surface functionalization 
The GO Chip is made of a gold patterned silicon substrate and a PDMS top layer.  Chips 
were fabricated and functionalized as previously described [21]. In brief, PDMS top layer was 
fabricated using standard soft lithography. Master molds were fabricated using SU8-2025 
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photoresist (Microchem Corp.). A 10:1 ratio of polydimethylsiloxane (PDMS) polymer to curing 
agent (Dow-Corning) was well mixed and de-bubbled prior to pouring over the SU8 molds. 
After curing at 65⁰C for over 6 hours, PDMS were manually cut from the mold, trimmed to size, 
and inlet/outlet holes were punched. Cr and Au films were deposited onto a silicon oxide coated 
silicon wafer by evaporation and were patterned by conventional photolithography. Patterned 
silicon substrates were dipped in a GO suspension for 10 minutes and rinsed with DI water and 
isopropanol. Then a silicon substrate and a PDMS chamber were bonded by corona discharge 
treatment to form a microfluidic chamber. The device was infused with N-γ-maleimidobutyryl-
oxysuccinimide ester (GMBS) in ethanol.  After 30-minute incubation, the excess GMBS 
solution was washed out by ethanol. NeutrAvidin in phosphate buffered saline (PBS, Gibco) was 
flowed through the chip and incubated for 50 minutes.  Afterwards, the excess NeutrAvidin was 
washed out by PBS. A biotinylated antibody cocktail (anti-EpCAM, anti-CD133 and anti-EGFR 
at a concentration of 10µg/mL) was flowed through the chip and incubated for 30 minutes.  After 
washing with PBS, 3% bovine serum albumin (BSA, Sigma-Aldrich) blocking solution was 
injected and incubated for 30 minutes.   
2.3.2 Cell preparation  
Cell culture reagents were purchased from ThermoFisher Scientific unless otherwise 
specified. H1440 (provided by David Beer lab) and H1650 cells (purchased??) were cultured in 
RPMI medium containing 10% fetal bovine serum and 1% penicillin–streptomycin solution. 
When cells reached 70–80% confluence, they were collected. To perform the capture efficiency 
experiments, cells were labeled with a green cell tracking dye (Invitrogen, CellTracker Green 
CMFDA, C7025).  
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2.3.3 Human Blood Sample Collection and Processing 
Blood samples were drawn from NSCLC patients and healthy donors after obtaining 
informed consent under an IRB-approved protocol. All samples were collected in EDTA tubes 
and were processed within 3 hours. 1 ml blood was flowed through each device at 1 mL/hr by a 
syringe pump. After flowing blood, the captured cells were washed with PBS, fixed with 
4% paraformaldehyde (PFA), and stored at 4°C until immunofluorescent staining. 
2.3.4 Immunofluorescence Staining of Isolated CTCs 
Cells were permeabilized with 0.2% Triton-X (Sigma-Aldrich) and incubated for 30 min 
followed by a PBS wash. The device was incubated for 30 min with blocking buffer containing 
2% normal goat serum and 3% BSA. Anti-cytokeratin(Pan) (Bio Rad), anti-CD45 (Bio Rad) and 
anti-PD-L1 (BioLegend) were antibodies were flowed through the graphene oxide chip,  
incubated for 1 h, and washed with PBS. Anti-cytokeratin(Pan), anti-CD45 and anti-PD-L1 were 
probed respectively with Alexa Fluor 546 IgG1 (Invitrogen),  Alexa Fluor 488 IgG2a 
(Invitrogen), and Alexa Fluor 647 IgG2b (Invitrogen). These secondary antibodies were flowed 
through the graphene oxide chip, incubated for 1 h, and washed with PBS. To stain the nuclei of 
the captured cells, DAPI (4',6-Diamidino-2-Phenylindole, Dihydrochloride) (Invitrogen) was 
flowed through the device. The device was incubated for 15 min and washed with PBS. The 
device was imaged using Nikon Eclipse Ti fluorescence microscope. 
2.3.5 RNA extraction and RT-qPCR 
Arcturus PicoPure RNA Extraction buffer (Life Technologies) was flowed through the 
chip to lyse the captured cells immediately after PBS wash. After incubation at 42 °C for 30 min, 
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the device was washed with water and the effluent were collected. The effluents, which were the 
total RNA samples, were stored at -80 °C until cDNA preparation. The cDNAs were synthesized 
from the total RNA samples and then pre-amplified for the selected 96 genes using the 
corresponding pool of 96 TaqMan gene expression assays (Life technologies). The expression 
patterns of preamplified cDNAs for each sample were determined by qPCR using the same 
TaqMan gene expression assays and the BioMark HD system (Fluidigm). 
2.3.6 Statistical analysis 
Paired sample test the CTC counts and the proportion of PD-L1 (+) CTCs between 
different visits was compared by the Wilcoxon rank sum test using paired observations. The 
Wilcoxon rank sum test was done between the patients with disease progression and those with 
stable disease on the number of PD-L1 (+) CTCs. Differences were considered significant, if p 
value was less than 0.05. To analyze expression levels of selected genes between different 
patient groups, each transcript was normalized to the average of three house-keeping genes 
(HKGs: GAPDH, ACTB, and UBB), and reported as -ΔCT, where ΔCT = CT gene – CT (HKGs). The 
Ct values equal or above 35 was considered as no expression [104]. All data analysis was 
performed using R software. 
2.4 Results 
2.4.1  Isolation of lung cancer cells from model blood samples 
The performance of the GO chip for CTC isolation has been previously tested using 
breast and prostate cancer cell line[21]. To validate the performance of the GO chip for lung 
cancer, fluorescence labeled human lung cancer cell lines H1650 and H441 (1000 cells/mL) were 
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spiked into blood obtained from healthy donors and flowed through the GO chip at 1mL/hr. The 
capture efficiency of H441 and H1650 was 91% and 97% respectively (Figure 2.2A). 
The specificity of the PD-L1 antibody was tested by immunofluorescent staining of lung 
cancer cell lines. After capture on the chip, cells were stained for anti-Pan cytokeratin (CK) 
(tumor marker), anti-CD45 (leukocyte marker), anti-PD-L1 and DAPI (nuclear stain) and 
respective secondary antibodies. White blood cells were identified as positive for DAPI and 
CD45, while cancer cells were identified as positive for DAPI and CK, but negative for CD45. 
PD-L1 positive cell line H441 stained positive for PD-L1 (Figure 2.2C) while no PD-L1 
expression was detected in PD-L1 negative cell line H1650 (Figure 2.2B).  
 
Figure 2.2 Capture	efficiency	and	fluorescence	images	of	lung	cancer	cell	lines 
(A) Capture efficiency of lung cancer cell lines H441 (n=3) and H1650 (n=3). (B) Representative 
images of immunofluorescence staining of H1650 lung cancer cells along with WBCs captured 
on the chip. (C) Representative images of immunofluorescence staining of H441 lung cancer 
cells along with WBCs captured on the chip 
2.4.2 Isolation of CTCs in non-metastatic NSCLC patients undergoing 
radiation or radiochemotherapy 
Demographics of 12 NSCLC patients enrolled in this study are shown in Table 2.1. We collected 
serial blood samples from 12 patients with non-metastatic NSCLC who received radiation alone 
(n=4) or radiochemotherapy (n=8) (Table 2.1). Serial blood samples from the patients enrolled in 
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the study were collected at the following time points: before the initiation of treatment (visit 1), 
during treatment (visit 2), and at follow up at least one month after treatment (visit 3). The 
flowchart in Figure 1 provides an overview of the recruitment process and the method of CTC 
isolation.  Depending on the length of the treatment, we might receive multiple samples during 
treatment.  In these cases, we reported here the averaged CTC number for visit 2. 
Table 2.1 Demographics of patients 
Patient	 Age	 Sex	 Histology	 T	 N	 M	 RT	dose	 RT	fraction	size	 Concurr-ent	chemo	 Concurrent	chemo	drugs	 Adjuva-nt	chemo	Patient	1	 60	 Male	 Adenocarcin-oma	 2a	 1	 0	 60	 2	 No	 N/A		 No	Patient	2	 79	 Male	 Carcinoma	 2	 0	 0	 70	 2	 No	 	N/A		 No	Patient	3	 64	 Male	 Adenocarcin-oma	 1	 0	 	0	 	50	 	10	 	No	 	N/A	 No	Patient	4	 73	 Male	 Squamous	 1a	 3	 0	 50		 	5	 	No	 	N/A	 No	Patient	5	 72	 Male	 Squamous	 2a	 1	 0	 60	 2	 Yes	 Carboplatin/Taxol	 No	Patient	6	 67	 Male	 Sarcomatoid-	carcinoma	 3	 2	 0	 60	 2	 Yes	 Carboplatin/Taxol	 No	Patient	7	 65	 Male	 Squamous	 4	 3	 0	 60	 2	 Yes	 Carboplatin/Taxol	 No	Patient	8	 63	 Male	 Squamous	 2b	 0	 0	 60	 2	 Yes	 Carboplatin/Taxol	 No	Patient	9	 82	 Male	 Squamous	 3	 2	 0	 60	 2	 Yes	 Carboplatin/Taxol	 No	Patient	10	 60	 Male	 Adenocarcin-oma	 4	 3	 0	 60	 2	 Yes	 Carboplatin/Taxol	 Yes	Patient	11	 57	 Male	 Squamous	 1b	 3	 0	 60	 2	 Yes	 Carboplatin/Taxol	 No	Patient	12	 67	 Male	 Squamous	 2b	 2	 0	 60	 2	 Yes	 Cisplatin/	Etoposide		 No		
After cells were captured on the chips, GO chips were stained and imaged, and CTCs 
were identified as CK+/CD45−/DAPI+ cells. Figure 2.3A and Figure 2.3B shows representative 
micrographs of PD-L1 (+) CTC and PD-L1(-) CTC. While the majority of captured CTCs were 
single cells, clusters of 2- 4 CTCs were observed in most patients (10/12) (Figure 2.3C). Blood 
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samples from healthy donors gave a counting of 2 or 3 CTCs/ml and thus a threshold of ≥ 3 
CTCs /ml was used for CTC detection in patient samples (Figure 2.3D).  
 
Figure 2.3 CTC counts and images isolated by GO chip from different visits of 12 NSCLC 
patients 
(A) – (C) Representative images of CTCs isolated from NSCLC patients stained by antibodies 
against cytokeratin (red), a leukocyte marker CD45 (green), and a nuclear stain (DAPI).  (A) 
CK+/PD-L1+ CTC, (B) CK+/PD-L1- CTC, (C) CTC cluster.  Scale bar is 10 µm. (D) CTC 
enumeration from blood samples of healthy donors (n=3) and from blood samples of NSCLC 
patients (n=36). (E) Number of CTCs isolated by GO chip from blood samples from different 
visits of 12 NSCLC patients (P1 through P12). P1 stands for ‘patient 1’. Blue bar represents the 
number of CK+/PD-L1- CTCs. Red bar represents the number of CK+/PD-L1+ CTCs. 
 	
CTCs were detected in all samples with the average of 20.8 CTCs/ml (range 4-72) 
(Figure 2.3D, Table 2.2).  The average number of CTCs for visit 1, visit 2, and visit 3 were 29.2 
CTCs/ml, 20.3 CTCs/mL, and 14.6 CTCs/mL respectively (Table 2.2). For the eight patients 
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receiving radiochemotherapy (patient 5-12), a decrease in CTC numbers was observed in visit 2 
and visit 3 compared to visit 1 among 6 patients (75%) although it was not statistically 
significant (Figure 2.3D). Among the rest of the four patients who received radiation therapy 
only (patient 1-4), CTC numbers increased 10 folds and 3 folds during radiation in patient 1 and 
patient 4 respectively (Figure 2.3D, Table 2.3).   
Table 2.2 Statistics of total CTC number and PD-L1 (+) CTC number at different visits  
(Unit, cells per mL; SD: standard deviation) 
 
CTC range 
Average 
CTC 
SD for 
CTC 
Median 
CTC 
PD-L1 (+) 
CTC range 
Average 
PD-L1 (+) 
CTC 
SD for PD-
L1 (+) CTC 
Median 
PD-L1 (+) 
CTC 
Total 5 – 79 21.3 20.3 13.5 0 - 32 4.1 6.8 1.5 
Visit 1 5 – 79 29.2 27.1 18.5 0 - 14 2.6 4.2 1 
Visit 2 3.5-68 20.3 20.7 14.3 0 - 32 6.7 9.5 3 
Visit 3 5 - 32 14.6 8.5 12.5 0 - 17 3 4.7 1 
 
Table 2.3 A list of total CTC number, PD-L1 (+) CTC number and the fraction of PD-L1 (+) 
CTCs at different visits for 12 patients 
Patient 
Visit 1 Visit 2 Visit 3 
CTCs 
( /mL) 
PD-L1 (+) 
CTCs       
( /mL) 
Proportion 
of PD-L1 
(+) CTCs 
CTCs 
( /mL) 
PD-L1 (+) 
CTCs       
( /mL) 
Proportion 
of PD-L1 
(+) CTCs 
CTCs 
( /mL) 
PD-L1 (+) 
CTCs        
( /mL) 
Proportion 
of PD-L1 
(+) CTCs 
Patient 1 6 1 17% 68 32 47% 32 17 53% 
Patient 2 50 0 0% 15.5 0.5 3% 17 2 12% 
Patient 3 7 1 14% 5.5 3 55% 7 0 0% 
Patient 4 5 0 0% 21 3 14% 9 0 0% 
Patient 5 79 3 4% 57 21.5 38% 24 1 4% 
Patient 6 14 0 0% 13 1.5 12% 5 0 0% 
Patient 7 73 9 12% 21 8.5 40% 13 6 46% 
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Patient 8 50 14 28% 3.5 0 0% 12 5 42% 
Patient 9 9 0 0% 15.5 3.5 23% 22 4 18% 
Patient 10 23 0 0% 10 1.5 15% 5 1 20% 
Patient 11 28 1 4% 6 1.5 25% 20 0 0% 
Patient 12 6 2 33% 7.5 3.5 47% 9 0 0% 
 
2.4.3 CTCs and PD-L1 expression of CTCs in non-metastatic NSCLC 
patients undergoing radiation or radiochemotherapy 
PD-L1 (+) CTCs were detected in 24 samples (66.7%) with an average number of  4.7/ml 
(range  0-43) (Figure 2.3D, Table 2.3). The average number of PD-L1 (+) CTCs for visit 1, visit 
2, and visit 3 were 2.7 CTCs/ml, 6.7 CTCs/mL, and 3 CTCs/mL respectively (Table 2.2). The 
PD-L1 (+) CTCs number in visit 2 sample is significantly high compared to that in visit 3 (P = 
0.037) (Figure 2.4A). The proportion of PD-L1 (+) CTCs to total CTCs ranged from 0 to 61.4% 
with an average of 17.1% (Table 2.2). Compared to the proportion of PD-L1 (+) CTCs isolated 
before treatment (mean 7.1%, SD 8.6%), the proportion of PD-L1 (+) CTCs during treatment 
increased in 11 out of 12 patients (mean 28.3%, SD 24.7%) . This difference reached statistical 
significance (P = 0.0068) (Figure 2.4B), suggesting that radiotherapy or radiochemotherapy 
induces PD-L1 expression in CTCs.  
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Figure 2.4 Dynamic changes of PD-L1 (+) CTC proportions at different visits 
(A) Dynamic changes of PD-L1 (+) CTC proportions at visit 1, visit 2, and visit 3 for 12 patients. 
P1 stands for ‘patient 1’. Red bar represents the percentage of PD-L1 (+) CTC number in total 
CTC number. Blue bar represents the percentage of PD-L1(-) CTCs in total CTCs. (B) The 
fraction of PD-L1 (+) CTCs out of total CTCs in different visits (n=12). 
 
2.4.4 Prognostic significance of PD-L1 status in CTCs at baseline 
Patient 3 were lost to follow-up after 3 months. For the rest 11 patients, progression-free 
survival (PFS) was analyzed according to the baseline CTC number and PD-L1 (+) CTC 
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number. No significant difference in PFS was found in the patients with high CTC number 
(CTCs≥20 /ml) (median 9.9 months) compared to those with low CTC number (CTCs < 20/ml) 
(median 6.95 months).  The commonly used cutoff value for assessing PD-L1 positivity in tissue 
biopsy staining is 5% [105], which is close to the mean value of PD-L1 (+) CTC% (7.1%) at 
baseline.  If ≥5% of PD-L1 (+) staining among CTCs is used as cutoff for PD-L1 positivity, PD-
L1 positive patients have much shorter PFS as compared with PD-L1 negative patients (median 
6.7 months, range 5.7 – 9.9 month vs median ≥14.75 months, range 7.5 - 18.9 months: P=0.016) 
(Figure 2.5B). Notably, patient 1 who had high PD-L1 (+) CTC counts at visit 2 and visit 3 was 
put on therapy with PD-1 inhibitor pembrolizumab after initial progression and has had stable 
disease for  7 months. 
 
Figure 2.5 Kaplan–Meier life-table analysis of the PFS time in all patients. 
Kaplan–Meier life-table analysis of the PFS time in all patients. Grouping was done according to 
(A) CTC number more or less than 20/ml (B) PD-L1 (+) CTC% more or less than 5%. 			
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Table 2.4 Progression-free survival (PFS) of Patient. 
("NED" stands for "no evidence of disease") 
 
Patient  Status PFS (months) PFS censor 
Patient 1 Alive, Progressed 6.7 0 
Patient 2 Alive, NED 2.3 1 
Patient 3 Alive, NED 9.9 1 
Patient 4 Alive, NED 9.6 1 
Patient 5 Alive, NED 14.6 1 
Patient 6 Alive, NED 18.9 1 
Patient 7 Dead 6.5 0 
Patient 8 Dead 5.7 0 
Patient 9 Alive, NED 14.9 1 
Patient 10 Alive, NED 17.5 1 
Patient 11 Dead 7.4 0 
Patient 12 Alive, Progressed 7.5 0 	
2.4.5 Gene expression profiling of CTCs 
To further investigate the molecular signature of CTCs from patients and study the 
association with treatment outcomes, mRNA profiling of the captured CTCs was carried out by 
performing quantitative RT-PCR for selected panel of 96 genes consisting of lung cancer related 
genes, epithelial and mesenchymal genes and immune checkpoint-related genes (Table 2.5). 
After normalization to average of internal house-keeping genes (HKGs: GAPDH, ACTB, and 
UBB) using the ΔCt method, the PD-L1 mRNA expression at different visits were compared. 
Among visit 1 samples, 30% of the samples had detectable levels of PD-L1 mRNA expression. 
Whereas, 70% of visit 2 samples and 25% of visit 3 samples showed detectable PDL-1 gene 
expression (Figure 2.6A). The expression level of PD-L1 in visit 2 samples are significantly 
higher than those in visit 1 and visit 3 samples (P = 0.043 and P = 0.026, respectively), which is 
consistent with the results of PD-L1 (+) CTC number. To investigate the prognostic value of 
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CTC gene expression, patients were classified into poor prognosis (PP group) and good 
prognosis (GP group) based on a cutoff at 9 month PFS. This cutoff is chosen based on the 
median PFS time of patients. Five patients had disease progression within 9 months while the 
other seven patients had stable disease in a time period of 9 months or more. The mRNA levels 
of PD-L1 is detected in 9 out of 12 samples in PP group while the mRNA levels of PD-L1 is 
detected in 3 out of 14 samples in the GP group. The mRNA levels of PD-L1 were significantly 
higher in the samples from PP group than that of GP group (P = 0.025) (Figure 2.6B).  Similarly, 
from the results of IF staining, samples from PP group tend to have higher proportion of PD-L1 
(+) CTCs than those from GP group, although not reaching statistical significance (median 22% 
vs 7.8%, P=0.063, Figure 2.6C). MTOR gene which is related to PD-L1 upregulation in tumor 
cells [106] also displayed increased level of expression in PP samples(Figure 6D). In addition, 
Ki67 and CD33 were highly expressed in the samples from PP group (P = 0.042 and 0.042 
respectively) (Figure 2.6E and F).   
Table 2.5 The 96 gene panel for CTCs in NSCLC 
 
GAPDH TGFB1 CD20 BCL-xL CTNND1 FOXC2 MTOR SNAI1 
ACTB EMP2 CD45 BMi1 CXCL16 IGFBP5 MUC1 SNAI2 
UBB TROP2 EGFR CASP3 CXCR1 IL6 NFKB1 SPARC 
ALDH1A1 KRT5 KRAS CCND1 DSP IL8 NTRK2 STAT3 
ALDH1A3 KRT7 MKI67 CD146 ELF3 JUP PIK3CA TIMP1 
CD24 KRT8 AR CD33 ERCC1 KLF4 PKP2 TIMP2 
CD44 KRT14 PD-1 CD34 ERG KLK3 PSME3 TMPRSS2 
CD44v6 CDH1 PDL-1 CHP1 ETV1 LGALS3BP PTCH1 TP53 
CD133 CDH2 XIST COL1A2 EVPL MAPK1 PTEN XBP1 
EPCAM CDH11 HOTAIR COL3A1 FGF18 MLPH PTPRN2 XIAP 
ERBB2 CD3D ABCG2 CTNNA1 FOLH1 MMP2 RB1 ZEB1 
VIMENTIN CD11B ALK CTNNB1 FOXC1 MMP9 SERPINB6 ZEB2 
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Figure 2.6 mRNA profiling of CTCs. 
(A) mRNA level (-∆𝐶!) of PD-L1 in visit 1 samples(n=10), visit 2 samples(n=10) and visit 3 
samples (n=8); (B),(D)-(E) mRNA level (-∆𝐶!) of differentially expressed genes PD-L1 (B), 
mTOR (D), Ki67(D), and CD33 (E) in PP samples (n=12) versus GP samples (n=14). P-value < 
0.05 (*); (C) PD-L1 (+) CTC proportion in PP samples (n=15) versus GP samples (n=21). 	
2.5 Discussion 
Preclinical studies have demonstrated that the combination of radiotherapy and PD-1/PD-
L1 checkpoint blockade synergistically enhances antitumor immune activity and increase the 
treatment efficacy of either therapy alone [100], [101]. A suggested mechanism is that the 
inflammatory response after radiation up-regulates the PD-L1 expression in tumor cells and 
surrounding cells, resulting in an immune-suppressive microenvironment [100], [101]. These 
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findings, however promising, have not been validated in clinical settings for NSCLC. CTC 
isolation provides a noninvasive way to monitor PDL-1 expression in tumor cells over time. The 
feasibility of analyzing PD-L1 (+) CTCs has been demonstrated in breast cancer and NSCLC 
[107], [108]. In a recent study, the persistence of PD-L1 (+) CTCs detected by CellSearch 
System was shown to be correlated with immunotherapy resistance in 14 metastatic NSCLC 
patients treated with PD-1 inhibitor Nivolumab, indicating that PD-L1 (+) CTCs may be a 
marker of immunotherapy escape [108]. However, the small number of PD-L1 (+) CTCs 
detected cannot reflect the dynamic changes of PD-L1 expression. In this study, we were able to 
detect sufficient number of CTCs via the GO chip at different time points to monitor changes of 
PD-L1 expression. Several features of the GO chip contribute to the improved sensitivity of CTC 
isolation compared to conventional methods: 1) graphene oxide increases the surface area on 
which the tumor specific capture antibody was present, 2) microfluidic structure obtains 
optimized flow pattern for cell capture, 3) an antibody cocktail of anti-EpCAM, anti-EGFR and 
anti-CD133 enables the isolation of CTCs expressing variable levels of epithelial and 
mesenchymal markers. Furthermore, as the white blood cell contamination within the GO chip is 
very low, the captured CTCs maintained high purity and thus enabled downstream gene analysis 
[21].  
In this study, we demonstrated for the first time that PD-L1 expression in CTCs is up-
regulated through the course of radio(chemo)therapy in non-metastatic NSCLC patients. At 
baseline, 42.9% of samples showed PD-L1 staining in CTCs if a 5% threshold for positivity is 
used. This is in line with previous studies reporting that a range of 20% to 57.5% of solid biopsy 
samples from stage I-III NSCLC patients express PD-L1 [109]-[111]. During radiation, the PD-
L1 expression in CTCs increased significantly (P=0.018). This finding is consistent with the 
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results of preclinical studies and might represent a mechanism of tumor immune escape. 
However, it is still unclear whether PD-L1 expression is obtained in primary tumor before 
intravasation or could be acquired within the blood circulation. Future studies that compare the 
PD-L1 expression of tissue biopsies or surgical specimens with that of CTCs will be very helpful 
to investigate the mechanism of PD-L1 expression in CTCs and to understand the significance of 
PD-L1 (+) CTCs. 
Furthermore, we revealed that PD-L1 positivity in CTCs may serve as a prognostic 
marker among non-metastatic NSCLC patients receiving radiation or radiochemotherapy. If 
more than 5% CTCs showing PD-L1 staining is considered to be PD-L1 positive, PD-L1 positive 
patients have much shorter PFS compared with PD-L1 negative patients. A possible explanation 
is that these PD-L1 (+) CTCs reflect immunosuppressive tumor microenvironment which 
promotes tumor relapse. In addition, with the capacity of evading immune response in a foreign 
environment, PD-L1 (+) CTCs may have higher metastatic potential. Indeed, two patients who 
later developed metastases showed PD-L1 positivity at baseline. However, the current study is 
limited due to the small patient cohort and the limited follow-up interval. Future studies in a 
large cohort would be valuable to investigate the potential of PD-L1 (+) CTCs for predicting 
disease progression for this subgroup of patients. Notably, patient 1 with high PD-L1 expression 
(>50% CTCs expressing PD-L1) at follow-up time point (visit 3) was treated with PD-1 inhibitor 
pembrolizumab one month after the follow-up visit and the tumor has been stable till now for 7 
months. As 50 percent or more PD-L1 expression in tissue samples has been used as a predictive 
biomarker for pembrolizumab, PD-L1 expression in CTCs could serve as a biomarker for 
selecting and monitoring patients for pembrolizumab therapy. 
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Furthermore, as we examined the mRNA expression pattern of CTCs for a 96-gene panel, 
PD-L1, Ki67 and CD33 was found to be highly expressed in patients who had disease 
progression within 9 months compared to patients who had stable disease for 9 months or more. 
The differences of PD-L1 mRNA expression levels between different visits are similar to that of 
the PD-L1 (+) CTC counts via the immunofluorescent staining, further confirming our findings 
in the upregulation of PD-L1 during radiation. The high expression of PD-L1 mRNA in poor 
prognosis group also supports the prognostic value of PD-L1. The expression of Ki67, a 
proliferation marker, has been associated with chemoresistance and poor prognosis [112], [113]. 
Ki67+ CTCs were detected in various cancer types including NSCLC and is associated with 
shorter overall survival [55], [114]. CD33, a myeloid cell marker, has been shown to be 
upregulated in the adenocarcinoma of NSCLC compared to the adjacent non-neoplastic lung 
tissue because of the infiltrated myeloid cells in tumor tissue [115]. Furthermore, myeloid-
derived suppressor cells (MDSC), an immune-suppressive population of myeloid cells, can form 
clusters with CTCs to protect CTCs from immune surveillance and may facilitate the formation 
of distant metastases [62]. Thus CD33 mRNA signal we detected may come from myeloid cells 
adhering to CTCs. Indeed, we frequently observed clusters of CTC and CD45+ blood cells 
captured in the chip. It is also possible that this signal comes from the non-specific binding of 
CD33+ blood cells on the chip, as the overexpression of CD33+ MDSC is observed in the 
peripheral blood of advanced stage NSCLC and is associated with immune suppression [116].  
The high purity of captured CTCs within the GO chip enabled downstream gene analysis 
such as qPCR. However, as it is unrealistic to achieve 100% purity, mRNA was extracted from a 
mixed population of CTCs and WBCs captured in the GO chip. Thus the mRNA levels detected 
here contained signals from both CTCs and the blood cells. This limitation could be overcome by 
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developing single cell gene analysis technique to differentiate the CTC population with the 
contaminating blood cells.  
To create successful combinations of immunotherapy, radiation, and chemotherapy, 
many concerns need to be addressed such as how to select patients and how to choose the 
optimal treament regimen and sequence when combined with PD-1/PD-L1 inhibitors. CTC 
enumeration and molecular characterization can be a useful tool to help in this decision making 
process as CTCs can be sampled frequently without an invasive procedure. As we demonstrated 
the feasibility of monitoring PD-L1 (+) CTCs in this study, this CTC subgroup could potentially 
act as a biomarker to monitor the tumor immunity to facilitate treatment selection for 
combinational immunotherapies. Future efforts should incorporate dynamic monitoring of PD-
L1(+)CTC for the timed administration of PD-1/PD-L1 inhibitors such as pembrolizumab in 
patients with locally advanced NSCLC.  			
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CHAPTER 3 
 
3 Investigating the Potential of CTCs for Monitoring Tumor 
Status and Predicting Treatment Response in Locally 
Advanced Pancreatic Cancer 
	
3.1 Abstract 
The median overall survival of locally advanced pancreatic cancer patients ranges only 
from 9 to 10 months. For those patients, treatment options range from chemotherapy alone to 
combination of radiation therapy and chemotherapy. To improve the treatment outcome, there is 
a pressing need to develop biomarkers to monitor treatment response and to provide valuable 
information for treatment selection and adaption. CTCs can be isolated from peripheral blood of 
patients and hold the promise of being a real time biomarker for cancer detection and 
management. In this study, CTCs were isolated via the GO chip from blood samples taken at 
different time points during the course of chemotherapy and subsequent radiation therapy from 
26 patients with the locally advanced pancreatic cancer. Patients with decreased number of CTCs 
after chemotherapy had longer progression free survival (PFS) than patients with increase or no 
change in CTC counts prognosis (13.5 months vs 6.5 months, P value= 0.002), indicating that 
changes of CTC numbers may be an early indicator for treatment failure. Furthermore, the 
persistence of high expression of Vimentin, an epithelial-mesenchymal transition (EMT) marker, 
in CTCs is correlated with shorter PFS (7.55 vs 14 months, P=0.019). In mRNA profiling of 
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CTCs, the mRNA expression levels of three genes, BAX, CHK1 and EZH2 are associated with 
poor prognosis, which is in line with previous preclinical studies that these genes are involved in 
drug resistance. 
3.2 Introduction 
Pancreatic cancer is the 4th leading cause of death in the United States with a five-year 
survival rate of only up to 8% [80]. Approximately 30% of patients with pancreatic cancer are 
being diagnosed with locally advanced disease [122]. For these patients, systemic chemotherapy 
or any combined forms of radiation therapy and chemotherapy are typically the treatment options 
available. Although no evidence of metastasis is observed at the time of diagnosis, the median 
overall survival rate of those patients only range from 9 to 10 months. Pancreatic cancer is highly 
resistant to chemotherapy drugs, which leads to the failure of chemotherapy and thus contributes 
to the high mortality rate [123]. 
Several mechanisms and signaling pathways involved in the drug resistance process of 
pancreatic cancer have been proposed. For instance, it has been found that the cell cycle 
checkpoint proteins can help tumor cells escape the cytotoxic effects of the drugs by inducing 
cell cycle arrest for the repair of DNA damage caused by chemotherapy [124]. Therefore, the 
inhibition of cell cycle checkpoints such as Wee1 and CHK1 can sensitize the tumor cells to 
chemotherapy and enhance the treatment efficacy. Moreover, many recent studies have 
demonstrated that cancer cells with EMT phenotypes and stem cell properties play pivotal roles 
in treatment resistance [125]. Thus, analyzing the molecular signature of drug resistance in tumor 
samples from pancreatic cancer patients can assist the investigation of the resistance mechanism 
and the discovery of new therapeutic targets. Furthermore, in clinical practice, characterizing and 
monitoring the molecular feature of tumor cells for drug resistance markers is particularly 
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important for the prediction of treatment outcome in order to select the most effective therapy 
and limit the toxicity to patients. 
Currently, serial sampling of tumor tissues for molecular analysis during the course of 
treatment is impractical. Circulating tumor cells (CTCs) are tumor cells that are shed from tumor 
and enter the blood circulation and hold the potential to provide an alternative to biopsy for the 
real-time monitoring of tumor status. As CTCs can be easily sampled at various time points, the 
isolation and analysis of CTCs can substitute biopsies for monitoring the molecular features of 
pancreatic cancer to provide predictive and prognostic information for the selection of 
personalized treatment for patients. Evidence from recent studies showed that the presence of 
CTCs are associated with poor outcome [87], but relatively low levels of CTCs can be detected 
in most pancreatic cancer patients compared to other types of malignancies [5], [117].The 
limitation of current widely used technologies to detect CTCs in sufficient number in pancreatic 
cancer patients poses as a potential barrier for their use as an effective biomarker.	
Microfluidic technologies have emerged as a solution to isolate CTCs with high 
sensitivity and purity[4]. Previously we developed a nanomaterial based microfluidic chip, the 
GO chip, for capture and proteomic analysis of CTC [21]. The GO Chip consists of a 
microfluidic chamber and a substrate coated with graphene oxide (GO) nanosheets where the 
antibodies are tethered. This technology takes advantage of the increased surface area afforded 
by graphene oxide to achieve higher antibody coating density, thus improving sensitivity for 
CTC capture. Furthermore, antibodies are specifically patterned onto the flower patterns rather 
than the entire surface (as shown in Figure 1), which results in high purity of captured cells.  
In this study, we isolated CTCs using the GO chip from locally advanced pancreatic 
cancer patients and monitored the changes of CTC numbers over the course of treatment. Also 
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we characterized the captured CTCs using a DNA damage marker (H2AX) and an EMT marker 
(Vimentin) (Figure 3.1). Furthermore, mRNA expression of CTCs was analyzed using RT-PCR 
using a panel of genes specific to pancreatic cancer and resistance. Finally, we investigated the 
correlation between the numbers and the molecular features of CTCs and the patients’ clinical 
outcome to assess treatment outcome and disease progression among patients with locally 
advanced pancreatic cancer. 
 
Figure 3.1 An overview of this study. 
An overview of this study, with sample collection and circulating tumor cell (CTC) isolation at 
baseline, after chemotherapy and during radiation and months after treatment (follow up) 
3.3 Materials and Methods 
3.3.1 Patient selection and sampling 
We selected patients with histologic or cytologic proof of pancreatic cancer, for whom 
the treatment plan at the time of enrollment is chemotherapy and radiation therapy. Patients may 
be enrolled on other clinical trials. The target population of this study is locally advanced, 
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unresectable patients with no evidence of metastatic disease.  A total of 50 patients were planned 
to be enrolled for the study. Patients signed an informed consent indicating that they were aware 
of the investigational nature of this study, in keeping with the policies of UM hospital.  
Selected patients had blood samples drawn at the following time points: 
(1) At baseline, prior to the start of chemotherapy or radiation therapy for pancreatic 
cancer (if the patient already received chemotherapy for pancreatic cancer then this time point 
will be omitted).   
(2) After the first 3 weeks of induction chemotherapy are complete and prior to the start 
of radiation therapy.  Note: For patients receiving more than three weeks of induction 
chemotherapy an additional sample will be obtained after induction chemotherapy has been 
completed (and prior to the start of radiation therapy).  
(3) After completion of approximately 60% of the planned radiation dose (e.g. if 25 
fractions of radiation are planned the sample would be obtained no earlier than the 14th fraction 
and no later than the 19th).   
(4) After completion of radiation therapy and adjuvant chemotherapy.  Typically, this 
will occur one to two weeks after completing adjuvant chemotherapy. 
3.3.2 GO device Fabrication 
The fabrication and functionalization of GO chip has been previously described9. Briefly, 
gold films were deposited onto a silicon oxide coated silicon wafer by evaporation and were 
patterned by conventional photolithography. Graphene oxide nanosheets are absorbed onto gold 
patterns on the silicon substrate, then chemically functionalized with EpCAM antibodies. A 
polydimethylsiloxane (PDMS) layer were bonded with silicon substrate to forms a microfluidic 
chamber with a height of 50 µm and total volume of 45 µl.  
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3.3.3 Patient Sample Processing 
Patient blood samples were obtained according to the schedule described above. Most of 
the patients had 3 or 4 blood draws over the course of the study depending on the length of their 
induction chemotherapy. Within 3 hours of collection, blood samples were processed by GO 
chips at a flow rate of 1 mL/hr.  
3.3.4 CTC enumeration and characterization  
After sample processing, one chip containing bound CTCs were used for CTC 
enumeration and evaluating the expression of certain proteins by immunostaining. To 
differentiate captured CTCs and white blood cells, immunostaining was performed using anti-
cytokeratin(Santa Cruz), and anti-CD45(Bio Rad), where white blood cells were identified as 
positive for 4′ ,6-diamidino-2-phenylindole (DAPI) (Invitrogen) and CD45, a common 
leucocyte antigen, while CTCs were identified as positive for DAPI and cytokeratin (CK) or 
ZEB1, but negative for CD45. An additional marker, a DNA damage marker H2AX (Millipore) 
or an EMT marker Vimentin (BD), were used for immunostaining. 
The other chip were used for RNA analysis. RNA was extracted from captured 
circulating tumor cells with commercially available extraction kit, Arcturus	 PicoPure	 RNA	Extraction	buffer	(Life	Technologies). RNA Extraction buffer was flowed through the chip to 
lyse the captured cells immediately after PBS wash. After incubated at 42 °C for 30 min, the 
device were washed with water and the effluent were collected. The effluents, which were the 
total RNA samples, were stored at -80 °C until cDNA preparation. The cDNA was synthesized 
from the total RNA and then pre-amplified for the selected 96 genes using the corresponding 
pooled TaqMan gene expression assays (Life technologies). The expression patterns of 
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preamplified cDNA were analyzed by a quantitative polymerase chain reaction (qPCR) setting 
using the same TaqMan gene expression assays and the Biomark HD system (Fluidigm). 
3.3.5 Statistical analysis 
The number of CTCs and CTC subpopulations between different visits was compared by 
the Wilcoxon rank sum test. Logrank test was done for calculating the P value of Kaplan–Meier 
survival plot. if p value was equal to or less than 0.05, the differences were considered 
significant. To analyze expression levels of selected genes between different patient groups, each 
transcript was normalized to house-keeping gene GAPDH and reported as -ΔCT, where ΔCT = 
CT gene – CT GAPDH. If the CT values were above 40, which indicates that the amplification 
was not detected during the 40-cycle qPCR, it is regarded as off-scale data.  Therefore, an 
arbitrary cycle number of CT gene = 40 was assigned for numerical analysis36. All statistical 
analysis was performed using R software. 
3.4 Results 
3.4.1 Patient characteristics  
A total of 26 patients with locally advanced pancreatic cancer undergoing chemotherapy 
and subsequent radiation therapy were enrolled in our study for CTC isolation and analysis. The 
demographics of all patients are summarized in Table 3.1. For each patient, 2 mL of whole blood 
was processed at the following three time points for analysis (Figure 3.1): a. 3 weeks after 
completion of chemotherapy prior to the following radiation therapy (after-chemo); b. After an 
approximate of 60% of the scheduled radiation dosage was applied (during-radio); c. after 
completion of radiation and adjuvant chemotherapy (follow-up). An additional blood sample was 
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obtained from 12 patients who were treatment naïve at the time of study enrollment (baseline) to 
monitor and evaluate changes in CTC counts during treatment.  
Table 3.1 Patient information 
“Y” stands for “Yes”, “N” stands for “No”, and “N/A” stands for “Not available”. 
 
 
3.4.2 Monitoring changes in CTC number during treatment  
Each blood samples were processed through individual GO chips to quantify the number 
of CTCs from patients with pancreatic cancer. CTCs were identified using immunofluorescence 
staining showing positivity in pan-cytokeratin (pan-CK), DAPI, and negative for CD45. 
Concurrently, whole blood from healthy donors (n=3) was processed identically for negative 
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controls. The average CTC counts from healthy individuals were 2.67 /ml, ranges 2 ~ 3 
CTCs/mL, thus a 3 CTCs/mL threshold applied for CTC positivity in our analysis. Overall, 
CTCs were detected in 90.3% of blood samples. The mean number of CTCs for each visit 
(baseline, after-chemo, during-radio, and follow-up) was 31, 23, 14, and 21 cells/ml respectively 
(Figure 3.2A).  No statistical significance was observed in CTC numbers between samples after-
chemo, during-radio and follow-up time points. However, 12 out of 21 patients, for whom we 
collect blood samples for all four time points (who were treatment naïve at the time of 
enrollment), resulted in a significant decrease (P= 0.033) in CTC counts after chemotherapy 
compared to CTC counts prior to chemotherapy (Figure 3.2B). To correlate these results with 
clinical outcomes including progression free survival (PFS), patients were further divided into 
two groups depending on whether or not CTCs decreased after chemotherapy. Patients with 
decreased number of CTCs after chemotherapy experienced a longer PFS with statistical 
significance (13.5 months vs 6.5 months, P value= 0.002) than patients with increase or no 
change in CTC counts (Figure 3.2C), suggesting that CTC counts during the first cycle of 
chemotherapy may be a surrogate of sensitivity to chemotherapy. 
	 54	
 
Figure 3.2 Number of CTCs at different visits. 
(A) Number of CTCs isolated from blood samples of different visits among 12 treatment naïve 
patients (n=12). (B) Number of CTCs isolated from blood samples of different visits among 9 
patients who have been previously treated (n=8).  (C) Kaplan–Meier life-table analysis of the 
PFS time in 12 patients. Grouping was done according to the change of CTC number in after 
chemo sample compared to baseline sample. A decrease of CTC number in after chemo sample 
compared to baseline sample (red, n = 3) and an increase or unchanged CTC number in after 
chemo sample compared to baseline sample (blue, n = 9). 
 
3.4.3 Molecular characterization of CTCs using H2AX and Vimentin 
The phosphorylated histone H2AX, a marker for DNA double stranded breaks (DSBs), 
has been used for monitoring DNA damage in clinical trials of various chemotherapy agents 
[118]. To assess the DNA damages during treatment, we studied the H2AX expression of CTCs 
using IF in 4 patients. H2AX+ CTCs were detected in 10 out of 15 (67.7%) samples with a 
median number of only 1/ml (Figure 3.3). Interestingly, CK-/H2AX+/CD45- cells were 
frequently observed which might indicate that CTCs undergoes EMT and have decreased or lost 
CK expression. If CK-/H2AX+/CD45- cells could be considered as CTCs, patient W126 would 
have a high proportion of H2AX+ CTCs (92%) at the endpoint of chemotherapy, indicating that 
severe DNA damage in tumor cells was induced by chemotherapy. 
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Figure 3.3 CTCs stained with H2AX 
Number of CTCs isolated by GO chip from blood samples from different visits of 4 patients. 
Blue bar represents the number of CK+/H2AX- CTCs. Orange bar represents the number of CK-
/H2AX+ CTCs. Grey bar represents the number of CK+/H2AX+ CTCs.‘1’, ’2’, ‘3’ and ‘4’ in X 
axis represents visit 1, visit 2, visit 3, and visit 4 respectively.  
 
 
To further characterize EMT in CTCs, an additional marker vimentin (Vim) was applied 
to the captured CTCs using IF staining. Three CTC subtypes were identified including epithelial-
like (CK+/Vim-/CD45- cells), intermediate (CK+/Vim+/CD45- cells), and mesenchymal-like 
CTCs (CK-/Vim+/CD45- cells). Overall, CTCs with epithelial-like or intermediate phenotypes 
were more abundantly observed in our study population compared to completely mesenchymal-
like CTCs (Figure 3.4A). The median numbers of these epithelial, intermediate, and 
mesenchymal-like CTCs were 11.5, 11.5 and 1 cells/mL respectively. The median percentage of 
Vim+ CTCs (Vim + %) after-chemo, during-radio and follow-up samples were 63.5, 68.5, and 
32.4%, respectively (Figure 3.4B). The proportions of Vim+ CTCs in samples after-chem and 
after-radio were significantly high compared to that in follow-up samples (P=0.034 and P=0.014, 
respectively) (Figure 3.4C).  
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Samples were stratified into high expression (>30%) and low expression of vimentin 
(≤30%) based on Vim+%. The persistence of high vimentin expression in all three samples 
correlated with worse PFS (7.55 vs 14 months, P=0.019) (Figure 3.4D). 
 
Figure 3.4 CTCs stained with Vimentin  
 (A).CTC number of three CTC subtypes were identified, epithelial CTCs (CK+/Vim-/CD45- 
cells), intermediate CTCs (CK+/Vim+/CD45- cells), and mesenchymal CTCs (CK-
/Vim+/CD45- cells). (B) Number of Vim+ CTCs from blood samples of different visits among 
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3.4.4 mRNA profiling of CTCs  
To further investigate the molecular signature of CTCs related to treatment resistance and 
study their association with treatment outcomes, CTCs were isolated from 13 patient samples for 
mRNA expression analysis. Using quantitative RT-PCR, a selected panel of 96 genes consisting 
of pancreatic cancer related genes, DNA damage- and cell cycle-related genes, and EMT related 
genes were used (Table 3.2). The quality of RNA was verified by the internal control, GAPDH, 
which was also used as a housekeeping gene for normalization purposes. The RNA expression 
data was analyzed using the comparative Ct method (2-ΔΔCt) and correlated to PFS of patients 
with pancreatic cancer.   
We evaluated the prognostic value of genes expressed in CTCs at after-chemo visit 
among 13 patients. Patients with low expression of BAX, a pro-apoptotic gene, had 
shorter/worse PFS (8.15 vs 14.7, P value= 0.050) (Figure 3.5); whereas the high expression 
levels of CHK1 and EZH2 are also associated with shorter PFS (7.55 vs 9.2, P = 0.043; 6.8 vs 
9.6, P = 0.0023) (Figure 3.5).  
15 patients;	(C) The proportion of Vim+ CTCs in total CTCs from blood samples of different 
visits among 15. (D) Kaplan–Meier life-table analysis of the PFS time in 12 patients. Grouping 
was done according to the persistence of high vimentin expression (Vim+% > 30%) in three 
samples (after chemo, during radio and follow-up sample). Patients with high vimentin 
expression in these three samples (red, n = 4) and patients with low vimentin expression in one 
or more samples (blue, n = 8).  
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Figure 3.5 Kaplan–Meier life-table analysis of the PFS time for patient subgroups as 
defined by mRNA expression of different genes. 
Kaplan–Meier life-table analysis of the PFS time for patient subgroups as defined by mRNA 
expression of BAX (A), mRNA expression of CHK1 (B), and mRNA expression of EZH2 (C). 
The P value is calculated by logrank test. 
 
Table 3.2 The 96 gene panel for pancreatic CTCs. 
CDH1 CD20 EZH2 JUN WEE1 MCM10 PALB2 CDH1 
KRT7 CD33 BMi1 MMP2 CCNE1 MYT1 TROP2 KRT7 
KRT14 CD34 MUC1 MMP6 CCNE2 PARP1 COL1A2 KRT14 
KRT20 CD3D NES TIMP1  CDK1 RB1 ANXA2 KRT20 
MKI67 CD45 ATDC KRAS CDKN1A FBXW7 ANXA10 MKI67 
EPCAM CD56 TWIST1 BRAF CDKN2A HSP27 RRM1 EPCAM 
BAX CD66b ZEB1 cMYC CHK1 HSP90 RRM2 BAX 
BCL2 CD90 CDH2 CTNNB1 CTNNB1 HEY1  ERCC1 BCL2 
BNIP3 PIK3CA VIMENTIN JUN FBXW7 HIF1A hCNT1 BNIP3 
TYMP MTOR GLi1 MET TP53 MSLN SMAD4 TYMP 
TYMS AKT1 MUC1 STAT1 XRCC1 PDX1 TBX4 TYMS 
DPYD  MAPK1 TGFB1 ABL1 ATM CDA MYT1 DPYD 
 
3.5 Discussion 
Patients with locally advanced pancreatic cancer, which are unresectable, are typically 
treated with chemotherapy with or without radiotherapy. However, the survival rate beyond 2 
years is less than 10%. This poor clinical outcome has been closely associated with drug 
resistance [129]. Understanding the resistance mechanisms at the molecular level brings new 
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insights in designing new therapeutic strategies. Because these emerging therapeutic approaches 
target specific molecular abnormalities, molecular characterization of tumor cells has becomes 
critical for selecting appropriate therapy. Furthermore, since tumor cells can evolve and acquire 
resistance during treatment, monitoring tumor cells for the early assessment of treatment 
response is necessary to adapt therapy and limit toxicity in non-responding patients. The 
molecular analysis of circulating tumor cells (CTCs) holds potential as a ‘real time’ biomarker in 
monitoring treatment response and tumor progression and can potential guide the selection of 
personalized therapy. 
In this study, we quantified the number of CTCs among locally advanced pancreatic 
cancer patients and analyzed changes in its protein and gene expression levels of specific 
markers in these CTCs to correlate with the outcome of the patients.  
We first demonstrated that the CTC number tends to decrease during chemotherapy and 
that the reduction of CTC number after chemotherapy is associated with longer PFS.  This is in 
agreement with previous studies in lung cancer showing that the decreases in CTC number were 
associated with better treatment response and prognosis [71], [72]. These results indicate that 
change in the number of CTC can be used as surrogate biomarker for evaluating the 
effectiveness of chemotherapy. 
Standard chemotherapeutic drugs for pancreatic cancer such as gemcitabine and 5-
fluorouracil (5-FU) eliminate cancer cells because of their DNA damaging properties [130]. γ-
H2AX, a double-strand breaks (DSBs) has emerged as a biomarker to monitor the clinical 
response to DNA targeted therapies such as DNA damaging chemotherapy drugs, ionizing 
radiation or combinations thereof [118]. To evaluate the DNA damages in the tumors during 
treatment, we characterized CTCs using DNA damage marker H2AX in four patients. H2AX+ 
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CTCs were detected at a low level (median 1 cell/ml). Interestingly, in the after-chemo sample of 
patient W126, CK-/H2AX+/CD45- cells were detected at a level of 45 cells/ml. As CK-
/H2AX+/CD45- cells may be CTCs undergoing EMT, the elevated level of H2AX+/CD45- cells 
may indicate severe DNA damage in tumor cells during the treatment with Wee1 inhibitor and 5-
FU. Indeed, so far this patient has the longest PFS among all patients (PFS 20.5 months without 
progression).  
Because cytokeratin is down-regulated in mesenchymal cells, we may miss CTCs 
undergoing EMT if we use cytokeratin as the only marker. Furthermore, as EMT has been shown 
to induce resistance to treatment in pancreatic cancer [41], CTCs with EMT phenotypes may be 
important CTC subgroups to study. To investigate the EMT properties of CTCs, we 
characterized the vimentin expression of CTCs and identified three CTC subtypes: epithelial 
CTCs, intermediate CTCs, and mesenchymal CTCs. We observed the dynamic changes of the 
proportion of Vim+ CTCs (intermediate/mesenchymal CTCs), which greatly increased during 
the treatment. The persistence of high vimentin expression in CTCs in all samples during and 
after treatment is correlated with poor prognosis. We postulated that the abundance of Vim+ 
CTCs throughout the treatment might be an indicator of tumors undergoing EMT, which is a 
significant contributor to therapy resistance and leads to tumor progression.  
Furthermore, we profiled the mRNA expression of CTCs using a 96-gene panel to 
identify additional molecular features with prognostic value in pancreatic cancer. For samples 
taken at the endpoint of chemotherapy, mRNA expression levels of three genes, BAX, CHK1 
and EZH2 are associated with poor prognosis. BAX, a member of Bcl-2 protein family, is a pro-
apoptotic gene that induces cell death. BAX expression has been found to be a stronger indicator 
of survival in pancreatic cancer [132]. As an important regulator of G2/M checkpoint, CHK1 
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inhibits CDC25 in response to DNA damage and induces cell cycle arrest to allow the repair of 
damaged DNA before cells enter mitosis [133]. In addition, CHK involves in homologous 
recombination for DNA repair. Thus due to its role in DNA damage repair, CHK1 have been 
shown to contribute to therapy resistance of DNA damage agents. EZH2 is a member of the 
polycomb group (PcG) proteins that involve in the epigenetic control of gene expression. EZH2 
has been shown to play an important role in tumor growth, liver metastasis and cancer stem cell 
self-renewal activity in pancreatic cancer [134], [135]. Inhibitors for EZH2 and CHK1 and the 
induction of BAX have been shown to sensitize pancreatic cancer cells to chemotherapy agents 
and/or radiochemotherapy [119]. This is in concordance with our findings that the high 
expression of EZH2 and CHK1 and the low expression of BAX at the endpoint of chemotherapy 
correlate with shorter PFS. Thus our data support previous results in preclinical models, 
indicating that EZH2, CHK1 and BAX may be candidate therapeutic targets in treating 
pancreatic cancer [119]. Furthermore, because, as we have illustrated, detecting the expression of 
these genes during treatment is feasible, these genes could act as makers to predict and monitor 
the treatment response of chemotherapy for pancreatic cancer patients. 
The major limitation of the current study is the small sample size. The prognostic value 
of CTCs should be further validated in a larger cohort. Moreover, a longer follow-up time might 
allow for better evaluation of the prognostic value of CTCs. We will follow these patients in long 
term for future analysis. 
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CHAPTER 4 
 
4 Tunable Thermal-Sensitive Polymer-Graphene Oxide 
Composite for Efficient Capture and Release of Viable 
Circulating Tumor Cells 
* This chapter was previously published as H. J. Yoon, A. Shanker, Y. Wang, M. Kozminsky, Q. Jin, N. 
Palanisamy, M. L. Burness, E. Azizi, D. M. Simeone, M. S. Wicha, J. Kim, and S. Nagrath, “Tunable 
Thermal-Sensitive Polymer-Graphene Oxide Composite for Efficient Capture and Release of Viable 
Circulating Tumor Cells,” Advanced Materials, vol. 28, no. 24, pp. 4891–4897, Jun. 2016 [103]. 
4.1 Abstract 
The rarity of CTCs poses huge technical challenges for its isolation and down-stream 
analysis.  Immunoaffinity based technologies can harvest CTCs with high sensitivity and purity, 
but has the drawback of tethering cells within the device. Overcoming this limitation, a highly 
sensitive microfluidic system to capture circulating tumor cells from whole blood of cancer 
patients is developed. The device incorporates graphene oxide into a thermoresponsive polymer 
film to serve as the first step of an antibody functionalization chemistry. The LCST of around 13 
°C for the polymer matrix made it possible to process blood through the device at room 
temperature. As the temperature decreases to around 5 °C, captured cells can be released for 
subsequent analysis such as standard clinical cytopathological and genetic testing. Over 90% 
capture efficiency and release efficiency is achieved. Released CTCs were viable and structurally 
intact, enabling subsequent analysis such as standard clinical cytopathological and genetic 
testing. To demonstrate the CTC capture and release in clinical samples, we processed blood 
samples obtained from 10 metastatic breast cancer patients and 3 pancreatic cancer patients. 
	
	 63	
CTCs were successfully recovered from 10 out of 13 samples (ranging from 2 to 20 CTCs 
mL−1). Furthermore, we examined the feasibility of detecting HER2 amplification by 
fluorescence in situ hybridization (FISH). CTCs released from the chip were made into “cell 
blocks” to perform FISH analysis and HER2 amplification was detected in CTCs isolated from 
one breast cancer patient. The downstream analysis facilitated by the efficient release of captured 
cells highlights the potential for this device's use in basic and clinical cancer investigation. 
4.2 Introduction 
With over 1600 people dying of cancer in the United States every day [120],  the 
prevention of the second leading cause of death is a clear area of research interest in the medical 
community. The spread of tumor cells to distant locations in the body, or metastasis, is the cause 
of 90% of cancer related deaths [143], presenting an impetus for the study of those cells most 
responsible for cancer mortality. Circulating tumor cells (CTCs) are those cells shed from the 
primary tumor into the blood circulation, potentially en route to forming a secondary tumor, and 
are present at the incredibly low frequency of on the order of one in one billion normal blood 
cells in the peripheral blood of cancer patients [144]. CTCs can not only provide biological 
insight into primary and metastatic tumors but also have the potential to serve as real time 
biomarkers for making treatment decisions and monitoring drug efficacy [121]. Indeed, over 270 
clinical trials have now been proposed using CTCs as surrogate biomarkers [122]. However, to 
date, CTCs have not been incorporated into clinical practice for management of patients with 
cancer. The main challenges to this field include: (i) reaching the sensitivity needed to isolate 
these extremely rare cells from the surrounding blood cells (1 in 1 billion), (ii) minimizing 
processing to preserve the viability of cells, and (iii) achieving the specificity necessary to 
acquire pure population to enable meaningful genomic and functional analysis. 
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Microfluidic technologies have emerged as a solution to isolate live CTCs from small 
amounts of blood collected from cancer patients. A common separation technique involves 
immunocapture, the tethering of an antibody against a CTC-specific marker to a surface or 
structure to bind CTCs but not the normal blood cells. Functionalized microposts have been used 
in a number of CTC isolation devices [10], [14], [23]. Antibody-functionalized silicon 
microposts for CTC capture were used in the first microfluidic device designed for this purpose, 
the CTC Chip [123]. Subsequent microfluidic CTC capture devices also featured microfeatures 
coated with antibodies, such as the geometrically enhanced differential immunocapture (GEDI) 
chip [148], chaotic micromixer HB CTC Chip [19], high throughput microsampling unit 
(HTMSU) [16] and the HD-CTC module of an integrated system [149]. These immunocapture 
devices included features fabricated from polymers such as polydimethylsiloxane (PDMS), 
poly(methyl methacrylate) (PMMA), and cyclic olefin copolymer (COC). In order to push the 
field to realize the opportunities afforded by these cells, which may be captured at early stage as 
well as mid-metastasis, orthogonal techniques and materials would be necessary to enhance the 
sensitivity. Nanomaterials provide one such avenue, with advantageous properties such as a high 
surface area to volume ratio and a length scale on the order of magnitude of extracellular 
features. Many different classes of nanomaterials have been incorporated into CTC research [23], 
[124]. One example, graphene oxide (GO) has a number of proven biomedical applications 
[125]-[127]. We have recently developed a graphene oxide (GO) based device, the GO Chip, that 
took advantage of the increased surface area afforded by graphene oxide for highly sensitive and 
selective cell capture [21]. Using this method, we were able to demonstrate the capture of CTCs 
from peripheral blood samples from pancreatic, breast, and early stage lung cancer patients with 
low white blood cell contamination. However, this device shares the common drawback across 
	
	 65	
most immunoaffinity based technologies reliant on antibodies attached to a surface: the 
limitation of post-capture analysis because of difficulty in releasing viable cells from the capture 
substrate.  
Thermoresponsive polymers, a class of stimuli-responsive polymers that respond to 
temperature changes by undergoing conformational changes, have found wide applications in 
drug delivery,  tissue engineering [128], controlling cell adhesion [129] and bacterial growth 
[130], protein encapsulation [131], and the release of captured CTCs from the surface of such 
capturing devices [132], [133]. Alternative CTC release techniques take advantage of alginate 
hydrogel [133], [134] or layer-by-layer assembled [161] degradable capture substrates. However, 
these approaches all feature performance limitations in throughput [134], purity requiring 
additional processing [18], ability to process blood collected by standard conditions,[133] 
immense fabrication facility requirements [18], [132], time-consuming chemistry [135], and 
inconvenient experimental temperature conditions [135].  
Graphene- and graphene oxide (GO)-based polymer composites are a new class of 
materials which combine the excellent properties of graphene, such as high surface-to-volume 
ratio, high Young’s modulus, and high thermal and electrical characteristics [136], with the easy 
processability of polymers. Such composites have found uses in fields ranging from energy 
storage [137] and electronic devices [138], [139], to biomedical applications such as drug and 
gene delivery [140], cancer therapy [141], cell differentiation [142], [143], coating of biomedical 
implants [144], [145], and bio-imaging [140].  
We hypothesized that the combined advantages of a biocompatible functionalized 
nanomaterial with a thermoresponsive polymer that promotes effective cell release could address 
the challenge of sensitive capture while simultaneously allowing viable cell release. This could 
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lead to improvement in downstream analysis such as fluorescence in situ hybridization (FISH), 
molecular analysis, and single cell analysis. We present a new tunable thermal-sensitive 
polymer-GO Chip for highly efficient capture and subsequent release of CTCs incorporated into 
a microfluidic device (Figure 4.1A).  
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Figure 4.1 Schematic concept of a polymer-GO microfluidic device 
(A) Schematic concept of a polymer-GO microfluidic device for the capture/release of CTCs. (B) 
Enclosure within polydimethylsiloxane chamber and photograph of patient blood samples being 
processed by the polymer-GO devices.  
 
4.3 Materials and Methods 
4.3.1 Polymer Synthesis 
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N-acryloyl piperidine was synthesized through reaction between acryloyl chloride and 
piperidine (Figure 4.1A) [146]. In short, 0.11 mol of piperidine and 0.12 mol of triethylamine 
were dissolved in 100 mL of dichloromethane maintained at 0-5oC. A solution of acryloyl 
chloride (0.10 mol) in 15 mL of dichloromethane was added drop-wise to the above solution 
over 2 hours under constant stirring. After complete addition, the reaction mixture was stirred at 
room temperature for 24 hours and was extracted with water and purified by column 
chromatography (hexane:ethyl acetate, 1:1) to yield colorless to light yellow liquid. N,N-
diethylacrylamide was passed through a basic alumina column prior to polymerization. AIBN 
was recrystallized from methanol before use. In a typical polymerization reaction, the required 
amount of monomers was dissolved in anisole and 0.3 mol% (of total monomer content) of 
AIBN was added to the solution. The reaction flask was completely sealed and the solution was 
purged with Argon for 20 minutes. The reaction was carried out at 65°C for 20 hours. After the 
reaction, all the solvent was evaporated at high temperature under vacuum to obtain white solid 
residue. The residue was re-dissolved in chloroform and then twice precipitated in ethyl acetate 
to obtain white solid mass. The precipitate was recovered and dried at 60°C under vacuum for 2-
3 days. 
4.3.2 Polymer Characterization 
The synthesized polymers were characterized by gel permeation chromatography (GPC, 
Waters Inc., 1515 Isocratic HPLC pump and 2414 RI detector) using 3 Styragel columns- HR2, 
HR3 and HR4 in series maintained at 35oC with chloroform as eluent (flow rate- 1 mL/min, total 
elution time- 40 min). The instrument was calibrated with polystyrene standards. LCST was 
ascertained by measuring UV-vis transmittance (Varian Cary 50 Bio) of a 0.1 wt.% aqueous 
solution of polymers as a function of temperature. A thermocouple was used for real-time 
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measurement of temperature, with the metal junction dipped in the cuvette during the 
measurement. For effective measurement, the polymer solution was cooled down to 2-3°C along 
with the metal cuvette holder to slow down the heating up of sample in ambient condition. CaCl2 
was placed inside the UV-vis spectrophotometer chamber to ensure humidity-free environment. 
This was necessary to prevent atmospheric water vapor from condensing on the cold cuvette 
walls. UV-vis spectrum was measured from 200-800 nm at every 0.2-0.5°C with more frequent 
measurements near the transition temperature. Transmittance at 400 nm was plotted against 
temperature and the temperature for 50% transmittance was noted as the LCST. Molecular 
weights and LCSTs of different polymer batches are noted (Table 4.1).  
Table 4.1 Molecular weights, PDI, and LCST of different batches of synthesized polymers       
used in the study 
 
Polymer Mn (kDa) Mw(kDa) PDI LCST (oC) 
P1 209.246 308.086 1.47 13.6 
P2 151.332 253.380 1.67 12.7 
P3 175.085 255.778 1.46 12.0 
P4 173.019 303.009 1.75 11.8 
 
Materials Kapton polyimide tape was purchased from Cole Parmer. Ethanol, acetone, 
chloroform, and isopropanol were solvent grade and were used without further purification. 
Surface modifying agents – (Heptadecafluoro-1,1,2,2-tetrahydrodecyl)trichlorsilane (HFTCS) 
and 2-methoxy(polyethyleneoxy)propyltrimethoxysilane (PEG-silane) – were purchased from 
Gelest Inc. Microscope glass slides were purchased from Fisher.  
 
4.3.3 Device Fabrication 
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The glass slides were sequentially washed with chloroform, acetone, and isopropanol via 
sonication for 5 minutes each. The glass slides were then air dried and treated in a UV-ozone 
generator for 30 minutes to remove any carbon contamination and to obtain a high density of 
surface hydroxyl groups. The cleaned substrates were patterned using Kapton tape by masking 
the active device area. Kapton tape was chosen for its impermeability to silane vapors and good 
stability at high temperatures. The patterned substrates were then cleaned with wipes dipped in 
ethanol to remove any adhesive residue and treated with HFTCS via vapor phase surface 
modification at 100°C for 30 minutes. HFTCS treatment results in hydrophobic fluoroalkyl 
groups on the unmasked peripheral regions of the substrates which prevent the use of any 
physical confining barrier to pattern the device with polymer-GO film by drop-casting method. 
After HFTCS treatment, the Kapton tape mask was removed and the glass slides were washed 
with copious amounts of ethanol to remove any physisorbed silane as well as any adhesive 
residue. The second surface modification was done in liquid phase by immersing the glass slides 
in 3.35mM of PEG-silane in ethanol for 12-15 hours. Subsequently, the glass slides were again 
washed with ethanol to remove any physisorbed silane. A polymer-GO blend solution containing 
10 mg/mL of polymer in 975 µL DMF and 25 µL of GO-PEG solution was then drop-casted in 
requisite amount on the surface modified glass substrates and allowed to dry at 60°C in an oven. 
The PDMS chamber was assembled on the glass substrate with polymer-GO composite film 
through corona discharge to produce a microfluidic device (Figure 4.2). 
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Figure 4.2 Schematic for CTC device fabrication 
4.3.4 Fluorescent biotin assay 
To verify the ability to immobilize biotinylated antibody to the polymer-GO film surface, 
surface coverage by a fluorescently labeled biotin (Biotin (5-fluorescein) conjugate, Sigma 
Aldrich) was assessed (Figure 4.3A). Three polymer-GO films underwent the entirety of the 
conjugation chemistry (i.e. treatment with the GMBS crosslinker and NeutrAvidin; termed 
“Condition”) with fluorescent biotin addition as the terminal step. To account for non-specific 
binding, three polymer-GO films were treated only with the fluorescent biotin to serve as a 
control in an analogous fashion to an isotype control (termed “Control”). ImageJ was used to 
quantify the fluorescence. This technique showed a statistically significant increase in 
fluorescence intensity relative to the control (Figure 4.3B). 
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Figure 4.3 Fluorescent biotin assay to verify the immobilization biotinylated antibody. 
(A) Schematic represents fluorescent biotin assay and negative control. (B) The full conjugation 
chemistry features statistically higher fluorescence than the negative control as assessed via 
optical density (p = 0.019). 
 
4.3.5 Cell labeling for optimization experiments 
Cells were stained with CellTracker™ Green CMFDA Dye (ThermoFisher Scientific) 
according to the manufacturer’s protocol. The staining process takes approximately two hours 
and was performed in parallel with device preparation. 
4.4 Results 
4.4.1 Thermal-Sensitive Polymer-Graphene Oxide Composite Synthesis 
In the current work, the microfluidic device bottom substrate was coated with a 
composite film of functionalized GO dispersed in a matrix of thermoresponsive polymer with a 
lower critical solution temperature (LCST) of 13°C. Surface available functionalized GO 
(described below) provided anchors for attaching the CTC capture antibody while the polymer 
matrix provided temperature dependent modulation of capture or release functionality. The 
microfluidic assembly facilitated the processing of patient blood samples within a simple planar 
device (Figure 4.1B). Drop-casting the polymer-GO blend on a patterned and surface modified 
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substrate made such a device cheap and easy to fabricate. Moreover, the LCST of around 13°C 
for the polymer matrix made it possible to use the device at room temperature as opposed to 
higher temperatures [18], such that there are no concerns about inadvertently releasing the cells 
during the capture step. Additionally, cell release occurred under gentle conditions, maximizing 
the viability of released cells. The consolidation of the advantageous properties of GO-based 
capture with superior release functionality of the chosen polymer yielded a device that enables 
the study of these clinically interesting cells without many of the shortcomings of past 
technologies (Table 4.2), while simultaneously presenting an easy, scalable fabrication method. 
Table 4.2 Comparison of CTC isolation technologies 
Both commercially available and recently developed CTC isolation technologies are compared 
across multiple relevant metrics and abilities, showing the high versatility and performance of 
the technology put forth in this work. [21], [71], [146]-[151] 
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To create a tunable thermal responsive polymer, copolymer poly(N-acryloyl piperidine-
co-N,N-diethyl acrylamide) was synthesized via free radical polymerization using AIBN as an 
initiator and was characterized for its molecular weight and LCST (Figure 4.4A). LCST was 
modulated by employing a copolymerization technique using two acrylamide monomers with 
different degrees of hydrophobicity: N-acryloyl piperidine (AP) and N,N-diethyl acrylamide 
(DEA). The homopolymers poly(N-acryloyl piperidine) (PAP) and poly(N,N-diethyl acrylamide) 
(PDEA) have LCSTs of 4oC and 25oC respectively [152]. The required capture/release 
modulation temperature for the CTC device can be achieved by changing the ratio of the two 
monomers in the copolymer. For example, a copolymer synthesized with 7:3 molar ratio of 
AP:DEA showed a critical temperature of around 12-13oC, which was used in this study (Figure 
4.4B).  
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Figure 4.4 Polymer-GO composite 
(A) Synthetic scheme for copolymer. (B) UV-vis transmittance vs temperature plots for different 
polymer batches. (C) SEM image of polymer-GO surface. Arrows indicate GO. (D) 
Fluorescence images of polymer-only and polymer-GO films. Dye incubation was done at 40°C. 
Scale bar: 20.0 µm. 
 
4.4.2 Antibody Functionalization Chemistry 
GO nanosheets were functionalized with phospholipid-polyethylene-glyco-amine 
according to an earlier reported method [21]. The polymer-GO nanocomposite films were 
prepared through drop-casting a DMF solution of polymer and functionalized GO. The drop-cast 
films were dried at 60°C in oven for 2-3 hours to yield 3-4 µm thick composite film. Figure 4.4C 
shows the SEM image of Polymer-GO composite surface. The polymer-GO microfluidic devices 
for cell capture and release were fabricated in two steps (Figure 4.2). Poly(ethylene glycol) 
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(PEG) is well known to render surfaces non-fouling [153]. The PEG monolayer was necessitated 
to avoid recapturing of the released CTCs on the glass substrate. In the first step, the polymer-
GO composite film was deposited on a patterned and surface modified glass substrate followed 
by assembly with a PDMS chamber to form a microfluidic device. In the second step, the device 
was functionalized by immobilizing anti-EpCAM on the surface available GO through a cross-
linker and avidin-biotin mediated bio-conjugation, providing cell capture/release functionality.  
To show the surface availability of the amine groups from the GO-PEG in polymer-GO 
composite films, the drop-cast films were incubated with 0.25mM aqueous solution of an amine 
reactive dye, FSE (5-(and-6)-carboxyfluorescein, succinimidyl ester; Life Technologies (C1311)) 
for 30 minutes at 40°C and then washed with copious amount of DI water. The dye treated films 
were then imaged with fluorescence microscope (Olympus BX51 coupled with Olympus DP71 
camera and EXFO X-cite Series 120 light source). While polymer-GO composite films showed 
bright green fluorescence from the surface tethered dye, polymer-only films showed very low to 
no fluorescence (Figure 4.4D). Though the possibility of physically adsorbed dye molecules 
cannot be completely ruled out, it is most likely that the dye molecules were primarily tethered to 
the surface through covalent bonding between the amine groups on film surface and 
succinimidyl ester groups on the dye, as suggested by large contrast in fluorescence intensity 
from polymer-GO and polymer-only films. Time dependence of dissolution of polymer-GO 
composite films in cold water was also determined. Dye treated films were dipped in cold water 
for different lengths of time and the fluorescence images before and after dipping were 
compared. Films were dipped in cold water (5°C) for 5, 10, 20, and 30 minutes, and in room 
temperature water (20°C) for 30 minutes. The beakers with the dipped films were kept on an 
orbital shaker to weakly simulate conditions in microfluidic devices where the films are 
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subjected to shearing by the flowing fluids. Figure 4.5 shows the fluorescent images of the films 
before and after dipping in water at 5°C. 
 
 
Figure 4.5 Fluorescence microscopy images of polymer-GO films in either cold (5°C) or 
room temperature (20°C) water. 
Fluorescence microscopy images of polymer-GO films incubated with FSE dye before and after 
being dipped in either cold (5°C) or room temperature (20°C) water for the specified time 
durations. Scale bar: 200 µm 
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To verify the steps of the conjugation chemistry, experiments were performed to compare 
capture by (1) a polymer film lacking GO alone; (2) a polymer film lacking GO with the addition 
of anti-EpCAM; and (3) the polymer-GO film with full conjugation chemistry. The two control 
films showed significantly lower levels of capture with the polymer film and the polymer film 
with antibody capturing at 6.4% and 11.0% the level of the full chemistry, respectively (Figure 
4.6A), with the increase in capture of the polymer with antibody condition a likely a result of 
physically adsorbed anti-EpCAM. This also suggests that very little of the capture antibody on 
the fully functional device is non-specifically bound. 
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Figure 4.6 Cell Capture and Release Efficiency 
(A) Capture efficiency of microfluidic devices featuring only the thermosensitive polymer, the 
thermosensitive polymer and non-specifically bound anti-EpCAM, and the polymer-GO film 
with specific conjugation chemistry as normalized by this last condition. (B) Cell capture 
efficiency of the microfluidic polymer-GO device at various flow rates evaluated using a breast 
cancer cell line (MCF-7). Error bars show standard deviations (n=6). (C) Capture efficiency of 
cell lines of varying origin and EpCAM expression levels. MCF-7 (n=8), PANC1, H1650, 
LNCaP, Hs578T (n=6). (D) Release efficiency of the microfluidic polymer-GO device (MCF-7 
cells were spiked into 1 mL of buffer or blood). (E) Fluorescence microscope images of devices 
after capture and release (MCF-7).  
	
4.4.3 Cell Capture and Release Efficiency 
To test the performance of the GO-polymer device for CTC capture, fluorescence labeled 
human breast cancer cell lines MCF-7 cells (1,000 cells/mL) were spiked into buffer and flowed 
through the GO-polymer device at different flow rates (1-10 mL/hr). The captured cells in the 
device and the non-captured cells collected in the waste were then counted. As expected, the 
capture efficiency decreased with flow rate. We observed that the efficiency rapidly decreased at 
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flow rates ≥ 5mL/hr. In the 1–3 mL/h range, the average capture efficiency was over 88.2% (n = 
6 at each flow rate) (Figure 4.6B) with the highest capture of 95.21% at 1mL/hr. To further 
investigate the effect of tumor type and EpCAM expression on capture efficiency, three high 
EpCAM expressing cell lines for various cancer types (MCF-7 breast cancer cells, LNCaP 
prostate cancer cells, and H1650 lung cancer cells), one low EpCAM expressing cancer-cell line 
(Panc-1 pancreatic cancer cells), and one EpCAM negative cancer cell lines (Hs578T breast 
cancer cells) were selected for capture experiments at the flow rate of 1 mL/hr. The cells were 
fluorescently labeled and spiked into buffer at a concentration of 1000 cells/ml. The results in 
Figure 4.6C indicate that the anti-EpCAM-coated GO-polymer device achieved high capture 
efficiency (84.93-95.21%) for EpCAM-positive cancer cells. In contrast, a relatively low number 
of EpCAM-negative cells (Hs578T) were captured. Furthermore, the device is comparably 
effective in capturing different tumor cells, indicating the robust sensitivity of the device.  After 
capturing cells on the devices, cell release experiments were carried out by flowing 1 mL PBS 
through the devices in a room maintained at 5°C at 100 µL/min (Figure 4.6E). Quantification of 
the cells in the devices before and after release showed an average cell release of 95.21% and 
91.56% in buffer and blood experiments, respectively (Figure 4.6D). The released cells are 
linked with GO nanosheets through the antibody-GO conjugation. Graphene oxide nanosheets 
have been demonstrated to have good biocompatibility and can enhance cell proliferation [154]. 
We tested the viability of the released cells by live dead assay, 91.68% of cells remained viable 
after release (Table 4.3). The high viability of released cells enables further cell expansion and 
functional experiments. 
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Table 4.3 Experimental results from Live/Dead assay (MCF-7). 
 
Device	
Live cells 
after release	
Dead cells 
after release	
Live/Dead (%)	
D1	 264	 22	 92.31	
D2	 353	 7	 98.06	
D3	 174	 10	 94.57	
D4	 270	 35	 88.52	
D5	 152	 27	 84.92	
Average	 91.68	
 
4.4.4 CTC Isolation and Analysis from Clincial Samples  
To demonstrate the CTC capture and release in clincial samples using the tunable 
polymer-GO composite film based device, we processed blood samples obtained from 10 
metastatic breast cancer patients and 3 pancreatic cancer patients. Whole blood samples collected 
into EDTA tubes were processed at a flow rate of 1 mL/hr. Following a washing step, cells were 
released from the chip and deposited/spun onto glass slides by a cytospin centrifuge. CTCs in 
these samples were identified as DAPI-positive (shown in blue) nucleated cells staining positive 
for tumor markers (cytokeratin 7/8, visualized with a secondary antibody tagged with Alexa 
Fluor 546, shown in red) and negative for leukocyte markers (CD45, visualized with a secondary 
antibody tagged with Alexa Fluor 488, shown in green) (Figure 4.7A, B). CTCs were 
successfully recovered from 8 breast cancer patient samples and 2 pancreatic cancer patients 
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(ranging from 2 to 20 CTCs/mL) (Figure 4.7C). The average number of CTCs recovered from 
breast samples was 5.6 CTCs/mL and from pancreatic samples was 8.3 CTCs/mL.  
 
Figure 4.7 CTC isolation and analysis from clinical samples 
(A) Fluorescence images of CTCs from breast cancer patient sample. Nucleated cells (blue) 
staining positive for cytokeratin 7/8 (red) and negative for the white blood cell marker CD45 
(green) were enumerated as CTCs. Scale bar = 10 µm. (B) CTC enumeration results from 10 
breast cancer patients and 3 pancreatic cancer patients. (C) Fluorescence in situ hybridization 
(FISH) image of CTCs of breast cancer patient sample Br10. HER2 (green)/centromere 17 
probe(red). 
 
Released CTCs were viable and structurally intact, and hence could be readily 
investigated via standard clinical cytopathological and genetic testing. Here, we examined the 
feasibility of detecting HER2 amplification by fluorescence in situ hybridization (FISH). CTCs 
released from the chip were subsequently made into “cell blocks” by first fixing them with 
ethanol and then embedding them in Histogel (Thermo Scientific). Blocks were then formalin 
fixed and stored in 70% ethanol until slide preparation. Blocks were paraffin embedded and 
sectioned at the University of Michigan Histology Core. FISH was conducted using probes for 
HER2 (BAC clone RP11-94L15) and chromosome 17 control probe (BAC clone RP11-100E5), 
revealing HER2 amplification in one breast cancer patient (Figure 4.7D). FISH hybridization and 
image capture were performed essentially as previously described [155]. One green signal 
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indicates the presence of one copy of HER2, while one red signal indicates one copy of 
centromere 17 probe; the multiple green signals in the figure imply HER2 amplification. 
The downstream analysis facilitated by the efficient release of captured cells highlights 
the potential for this device’s use in basic and clinical cancer investigation. Through the 
incorporation of a composite that combines the advantages of a temperature-sensitive modality 
and sensitive nanomaterial-enabled capture, the polymer-GO film that serves as the basis of this 
technology overcomes some of the key shortcomings of previous CTC capture technologies 
(Table 4.2). As evidenced by data obtained from physiologic solutions containing spiked labelled 
cancer cells from multiple cancers and the processing of primary breast and pancreatic cancer 
patient blood samples, isolation of these rare cells with this device is highly feasible, completing 
the first step to unlocking the research opportunities presented by CTCs.  
4.5 Conclusion 
Compared with other CTC isolation strategies, immunoaffinity based technologies 
harvest CTCs with high sensitivity and purity [156], but has the drawback of tethering cells 
within the device. Overcoming this limitation, we are able to collect viable and intact CTCs in 
suspension after immunocapture, making it ideal for various downstream analysis that requires 
the high integrity and purity of the targeted cell population, such as genotyping and single cell 
profiling.  This advanced analysis of CTCs could become a ‘real-time’ indicator to develop 
personalized therapy, as well as to bring valuable insights into the mechanism underlying cancer 
metastasis. Due to the low cost and ease of fabrication, this technology is scalable for 
commercialization. Future study will optimize it for large-scale clinical study and investigate its 
clinical utility for therapeutic marker discovery, treatment selection, and management.  
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CHAPTER 5 
 
5 HBGO chip for High Throughput Circulating Tumor Cell 
Isolation  
5.1 Abstract 
To improve the throughput for CTC isolation, we incorporated a herringbone mixer to the 
existing GO chip. We further optimized the design of the herringbone mixer to maximize the 
collision of cells with the substrate of microchannels, resulting in a herringbone (HB) GO chip 
(HBGO chip) for efficient CTC capture at high flow rate. The grooved-herringbone mixer consists 
of repetitive mixing units, each of which has a set of twelve chevrons staggered asymmetrically 
with another set of twelve chevrons. The average cell capture efficiency for the unmodified GO 
Chip dramatically dropped below 70% at 50 and 100 µL/min, and further decreased below 50% 
at 200 µL/min, whereas the HBGO Chip maintained a target yield of > 80% up to 200 µL/min 
with no significant decrease in overall capture efficiency. Moreover, up to a flow rate of 200 
µL/min, > 90% of cells were viable, which is equivalent to the cell viability at lower flow rates.  
We further analyzed the spatial distribution of the cells captured on the chip surface and 
investigated the correlation between the channel length and flow rates at different capture 
efficiencies (60%, 70% and 80%). At the flow rate ranging from 50 to 200 µL/min, there is a 
strong linear relationship between flow rate and the required channel length to achieve a specific 
capture efficiency. 
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5.2 Introduction 
Metastasis is responsible for over 90% of cancer-associated death. It is widely accepted 
that the development of metastatic disease is mediated by circulating tumor cells (CTCs) that are 
shed from the primary tumor and circulate through the bloodstream of cancer patients. 
Consequently, CTCs holds great potential to act as a biomarker in the area of predicting disease 
progression, real-time monitoring of tumor status, and identifying novel therapeutic targets. 
However, CTCs are rare with a frequency of only 1-10 present in one mL of patient blood 
surrounded by billions of blood cells, which poses significant challenges for CTC isolation and 
analysis.  
Microfluidic technologies have emerged as a solution to isolate CTCs as they 
provide large surface area-to-volume ratio and high precision flow control. Many microfluidic 
devices have been developed based on the immune-affinity based capture strategy, which takes 
advantage of proteins expressed on the cell membrane of CTCs but not on blood cells resulting 
in a high-purity isolation. Antibodies against antigens of tumor cells, such as the epithelial 
cellular adhesion molecule (EpCAM), are tethered to the surface of the microfluidic channels to 
capture CTCs. However, one major drawback of immune-affinity based capture devices is the 
low throughput, typically ranging from 1 to 3 ml blood per hour, which limits the blood volumes 
that could be analyzed. Small blood volume used for CTC analysis results in a statistical 
variability associated with rare event detection [88] and may fail to capture the inherent 
heterogeneity of CTCs.  
We have previously developed a nanomaterial based microfluidic device, the GO chip, 
which consists of a microfluidic chamber and a substrate coated with graphene oxide (GO) 
nanosheets where the antibodies are tethered [21]. The throughput of the GO chip for processing 
	 86	
blood samples is only 1mL/hr. This is because that under laminar flow condition within 
microchannels, cells follow streamlines and have minimal diffusion across the flow channel. 
Under high flow rates, cells are likely to flow out of the chamber without being in close 
proximity with the antibodies coated on the substrate of the GO chip (as shown in Figure 5.1A). 
Therefore, to improve the throughput of the current GO chip, we need to design a structure to 
disrupt the streamlines and maximize the interactions of cells with the antibody-coated substrate 
of the microchannels. 
Herringbone micromixer, which incorporates arrays of herringbone-like micro-structures, 
can enhance the transverse flow and generate chaotic mixing in microchannels [188]. The 
geometries of the herringbone micromixer has been studied to maximize and direct the cell -
surface interactions [189]. The incorporation of herringbone structure into several CTC isolation 
platforms has generated high capture efficiency at a relatively high throughput [19], [79], [157]. 
However, different from most of the devices in which antibodies are coated on both the bottom 
and the walls of microchannels, the GO chip needs to be engineered in a way that the flow 
pattern directs the cells to the substrate where the antibodies are present.  
 Herein, we optimized the design of the herringbone-mixing channel to maximize the 
collision of cells with the substrate of microchannels and developed a herringbone GO chip 
(HBGO chip) for high throughput CTC capture.  
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Figure 5.1 Design rationale of the HBGO-CTC Chip 
Schematic illustration and time elapse fluorescent image of the trajectory of cell flowing through 
the GO chip (A) and the HBGO chip (B). 
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5.3 Materials and Methods 
5.3.1 Fabrication of System Manifold and HBGO-CTC Chip 
The design of the system manifold was created by CAD software (Solidworks) and 
fabricated using a high-resolution 3D printer (Projet 3500 Max). An acrylic based resin, M3 
crystal, was used for the printing process for its mechanical integrity and biocompatibility. Each 
component including the pump, heparin injector, power source, and micro controller were placed 
in the designated compartment and enclosed. The production of the HBGO-CTC Chip involved 
two separate processes. First, to fabricate the chip substrate, Cr and Au was evaporated onto a 4-
inch silicon dioxide wafer and patterned. The wafer was then diced into individual pieces. Next, 
to fabricate the PDMS (polydimethylsiloxane) structure, a silicon master mold was created by 
standard photolithography. Negative photoresist (SU-8 2050, MicroChem) was patterned on a 4 
inch bare silicon wafer using two separate masks: one for the main fluidic channel (40 µm 
height) and the other for the herringbone grooves (60 µm). The height of each layer was 
measured after each process with a surface profilometer (Veeco Dektak 6M). PDMS pre-
polymer mixed with cross linkers at a 10:1 weight ratio was poured onto the mold, degassed, and 
baked in an oven at 65°C for 24 hours. The cured PDMS structure was then carefully peeled off 
and cut. At last, two through holes were punched at both ends of the channel to feed and connect 
tubing.  
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5.3.2 HBGO-CTC Chip Assembly and Surface Functionalization 
To chemically modify the chip surface, tetrabutyl ammonium hydroxide intercalated GO 
nanosheets grafted with phospholipid-polyethylene glycol-amine were prepared and assembled 
on the gold patterned silicone dioxide substrate as described previously [21]. [103]. The 
substrates and PDMS replicas were subjected to oxygen plasma treatment and bonded to form 
the final device. N-γ-maleimidobutyryl-oxysuccinimide ester (GMBS) was flowed through the 
chip using a syringe pump (Harvard apparatus) and incubated for 30 min. The chip was then 
flushed with 70% ethanol to pre-sterilize the inner chamber wall. Subsequently, neutravidin and 
biotinylated anti-EpCAM antibody was introduced followed by 3% bovine serum albumin 
(BSA) to block the remaining binding surface. 
5.3.3 Cell Culture and Labeling 
Human epithelial breast cancer cell line MCF-7 was purchased from the American Type 
Culture Collection (ATCC, LGC Standards). MCF-7 cells were cultured at 37°C with 5% CO2 
and maintained by regular passage in complete media consisting of Dulbecco’s Modified Eagle’s 
Media (DMEM) with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin solution 
(GIBCO®, Life Technology). When cells reached a confluency of 70-80%, they were collected 
and fluorescently labeled with green cell tracker dye (Invitrogen, CellTracker Green CMFDA, 
C7025) for cell capture experiments.  
5.3.4 Cell Viability Assay 
To measure cell viability after processing samples through the HBGO CTC-Chip, a 
live/dead viability/cytotoxicity assay kit (GIBCO®, Life Technology) was used. The chip was 
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washed with 1× PBS (phosphate buffered saline, GIBCO®, Life Technology) after capturing the 
cells. Subsequently, a live/dead reagent consisting of calcein AM and ethidium homodimer-1 
was prepared according to the manufacturer’s instruction and applied. Following 30 min 
incubation, cells were imaged and manually counted under a fluorescent microscope for 
quantification. 
5.4 Results and discussion 
5.4.1 Design of HBGO CTC-Chip 
The HBGO-CTC Chip consists of a 24.5 × 60 mm silicon dioxide substrate with gold 
patterned thin film layer bonded to a polydimethylsiloxane (PDMS) structure containing four 
bifurcating microchannels with herringbone grooves embedded on their top surface. Functional 
GO nanosheets are assembled onto the gold layer presenting high density of anti-EpCAM 
antibodies on the substrate surface through chemical cross-linkers (Figure 5.2A). The geometry 
of the herringbone structure has been determined based upon previous designs used for chaotic 
mixing at low Re number (laminar flow). However, in order to maximize the cell to substrate 
contact frequency, unlike early devices where the interaction mainly takes place near the 
grooves, several modifications have been applied for optimization.  
The grooved-herringbone (HB) mixer consists of repetitive mixing units, each of which 
has a set of twelve chevrons staggered asymmetrically with another set of twelve chevrons. 
(Figure 5.2B). The distribution of these points where a vertical drag force is induced by adjacent 
micro vortexes increased the chance for cells to be directed toward the antibody coated substrate. 
The dimension of the groove height, width, and spacing was also adjusted to decrease the 
hydraulic resistance in the groove. This unbalanced resistance between the channel and grooves 
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increased the overall fluidic circulation by deflecting a significant portion of fluid and cells into 
the groove, and subsequently, improved the interactions of cells with the channel bottom when 
cells exit he grooves. Cells flowing through the herringbone moved in a zigzag trajectory until 
captured which increased its traveling time and distance within the chip (Figure 5.1B).  Forbes et 
al. demonstrated that the ratio of the groove width and the groove spacing has a significant effect 
on the pattern and frequency of particle-surface interaction[191]. The simulation results showed 
that when the groove width increased to over 3 times of the groove spacing, the hydraulic 
resistance in the groove decreased significantly, allowing for a large portion of the particles in 
the fluid to enter and flow along the grooves. Therefore, the groove width was selected to be four 
times of the groove spacing to maximize the surface contact of the streamlines with the channel 
bottom for high-performance cell capture (Figure 5.2B). The final dimension of the PDMS 
structure was as followed: overall height of the main fluidic channel was 40 µm, with a groove 
height set to 60 µm; the groove pitch and width was 200 and 160 µm respectively and the angle 
between the chevrons was 45°.  
 
	 92	
 
Figure 5.2 Characterization of the HBGO-CTC Chip 
(A) Schematic of the chip demonstrating the device dimension and the surface chemistry. (B), 
the layout of the herringbone structure with detailed parameters and SEM image illustrating the 
structure of the herringbone grooves. (C), Comparison of the CTC capture efficiency using the 
GO-CTC chip and HBGO-CTC Chip. Time elapse fluorescent image showing the trajectory of 
cell with in the two chips. (D), Cluster of tumor cells captured on the chip, labeled with green 
cell tracker dye and stained with a nuclear stain (DAPI). (E), the viability of tumor cells captured 
on the chip at 200 µL/min using LIVE/DEAD assay, live cells stained with Calcein-AM (green) 
and dead cells with EthD-1 (red). 
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5.4.2 Evaluation of HBGO-CTC Chip by Capture of Cancer Cell Lines 
To validate the performance of the HBGO-CTC Chip for CTC capture at high flow rates, a 
flat chamber GO-CTC Chip previously reported was used for comparison. Human breast cancer 
cell-line, MCF-7 cells were labeled with a fluorescent cell-tracker dye and spiked into 5 mL of 
PBS buffer solution with a concentration of 50-200 cells/mL. After processing the samples, both 
cells captured on-chip and non-captured cells collected in waste were counted to calculate the 
capture efficiency. At a flow rate of 1 mL/hr (16.67 µL/min), where most affinity based 
microfluidic devices operate, the GO chip showed high capture efficiency (mean yield > 90%) 
[21]. However, at higher flow rate, the average cell capture efficiency for the GO-CTC Chip 
dramatically dropped below 70% at 50 and 100 µL/min, and further decreased to below 50% at ≥200 µL/min. In contrast, the HBGO-CTC Chip maintained a target yield of > 80% up to 200 
µL/min with no significant decrease in overall capture efficiency which indicates that the 
herringbone mixer improved cell surface interaction (Figure 5.2C). The drop of capture 
efficiency of GO chip at high flow rate is due to two reasons: (1) the reduced resident time that 
the cells flow through the chip; (2) the increased shear force to overcome the cell adhesion force 
or disrupt adhesion bonds [158]. Whereas, The HBGO-CTC Chip achieves high capture 
efficiency up to 200 µL/min because of the improved interactions of cells with the channel 
bottom and the increased resident time of cells moving in the zigzag trajectory. 
 In addition, cell viability was assessed at different flow rates to determine the effect of 
shear force induced by increasing flow rates during the isolation process. Cell viability was one 
of the critical factors as low viability could adversely affect further downstream analysis of the 
captured cells. Greater than 90% of cells remained viable at the flow rate of 200 µL/min (Figure 
5.2D). Moreover, majority of cell aggregates spiked into buffer to mimic CTC clusters preserved 
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their shape and were intact upon isolation. However, at 300 µL/min, the high shear stress results 
in the significant decrease of the cell viability (70%) and the dissociation of cell aggregates. 
The spatial distribution of the captured cells along the channel was also analyzed by 
dividing the flow chamber of the chip into ten areas (the length of each area is 5mm) (Figure 
5.3A). At a flow rate of 50 µL/min, a wide spread distribution was observed in the GO Chip, 
whereas most cells were captured near the inlet of the HBGO Chip. Over 70% were captured 
within the first 20% of the device. When the flow rate increased to 300 µL/min, the location of 
these cells became more scattered along the chip resulting in a mean yield of <70%. We further 
investigated the correlation between the minimum required length of the channel and the flow 
rates at different capture efficiencies (60%, 70% and 80%) (Figure 5.3B). At the range of 50 ~ 
200 µL/min, a strong linear relationship between the flow rate and the required channel length to 
achieve a specific capture efficiency was observed (Figure 5.3C). We speculated that the channel 
length increased linearly in order to compensate for the reduced duration that cells interacts with 
the substrate per unit length at higher flow rate. However, as the flow rate increased from 100 
µL/min to 300 µL/min, the required channel length appeared to increase exponentially to achieve 
a capture efficiency of 60%, which may be caused by the increased shear disrupting the antigen-
antibody bonding, in addition to reduced residue time. These results provide us rationale for 
optimizing the chip geometry and selecting the proper flow rate. For instance, at the flow rate of 
50 µL/min, the channel length could be decreased to 30 mm to achieve 80% capture efficiency 
while minimizing possible cell damages caused by shear stress. Higher flow rates could be 
achieved by increasing the width of the channels or by stacking multiple chips together. 
As only a few data points are available, the interpretation of graphical data may be 
adversely affected by random errors in experiments. For future study, the relationship between 
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channel length and flow rate will be further investigated using a single unit cell of the HBGO 
chip, which is 1/4th the width and twice the length of the original chip. Due to the difference in 
scale, the flow rates tested in the unit cell should be 1/4th of those in the full size HBGO chip. The 
capture efficiency and the distribution of captured cells along the chip will be characterized at 
the flow rate ranges from 10 to 100 µL/min.  
 
 
 
Figure 5.3 The spatial distribution of the cells captured on the HBGO-CTC Chip 
(A), Spatial distribution of the captured CTC captured along the channel. (B), The 
relationship between the minimum required channel length and the flow rate at different 
capture efficiencies (60%, 70% and 80%). (C), The linear relationship between the flow 
rate and the required channel length to achieve a specific capture efficiency (60%, 70% 
and 80%). 	 				
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CHAPTER 6 
 
6 Conclusions  
	
6.1 Summary of Research 
6.1.1 Monitoring dynamic changes of PD-L1 (+) CTCs during 
radio(chemo) therapy in NSCLC  
The feasibility of monitoring dynamic changes of PD-L1 (+) CTCs is demonstrated 
among 12 NSCLC patients undergoing radiation or radiochemotherapy. CTCs were detected in 
all 36 samples (100%), and PD-L1 (+) CTCs were detected in 24 samples (66.7%). After the 
initiation of radiation or radiochemotherapy, the proportion of PD-L1 (+) CTCs in total CTCs 
increased significantly, indicating the upregulation of PD-L1 expression in tumor cells during 
radiation. This validates previous findings in preclinical models that PD-L1 expression in the 
tumor environment increased after the initiation of radiation, which provides a rationale for the 
combination of anti-PD-1/PD-L1 immunotherapy and radiation therapy. In addition, patients 
who were PD-L1 positive (> 5% of CTCs stained with PD-L1) at baseline had shorter PFS time, 
suggesting that PD-L1 expression in CTCs may have prognostic value among non-metastatic 
NSCLC patients. 
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6.1.2 Investigating the potential of CTCs for monitoring tumor status 
and predicting treatment response in locally advanced pancreatic 
cancer 
CTC isolation and analysis may act as a ‘real time’ biomarker to monitor treatment 
response for pancreatic cancer patients. In this study, CTCs were isolated via the GO chip from 
blood samples taken at different time points during the course of chemotherapy and subsequent 
radiation therapy among 26 patients with the locally advanced pancreatic cancer. Either the 
increase of CTC number after chemotherapy or the persistence of high expression of Vimentin in 
CTCs throughout the treatment course is correlated with poor prognosis. In mRNA profiling of 
CTCs, the expression levels of three genes, BAX, CHK1 and EZH2, are associated with poor 
prognosis, which is in line with previous preclinical studies showing that these three genes are 
involved in drug resistance. This study highlights the clinical utility of assessing the molecular 
features of CTCs and monitoring the changes of CTCs over the treatment course. 
6.1.3 Tunable Thermal-Sensitive Polymer-Graphene Oxide Composite 
for Efficient Capture and Release of Viable Circulating Tumor Cells  
A highly sensitive microfluidic system to capture circulating tumor cells from whole 
blood of cancer patients is presented. The device incorporates graphene oxide into a 
thermoresponsive polymer film to serve as the first step of an antibody functionalization 
chemistry. As the temperature decreases to around 5 °C, the polymer-GO composite detaches 
from the microfluidic chamber, and subsequently captured cells are released and thus become 
available for standard clinical cytopathological and genetic testing such as fluorescence in situ 
hybridization (FISH). Over 90% capture efficiency and release efficiency is achieved. CTCs 
were successfully recovered from 10 out of 13 samples (ranging from 2 to 20 CTCs/mL). HER2 
amplification was detected via FISH analysis from released CTCs from a breast cancer sample.  
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The downstream analysis facilitated by the efficient release of captured cells highlights the 
potential for this device's use in basic and clinical cancer investigation. 
6.1.4 HBGO chip for High Throughput Circulating Tumor Cell Isolation 
A high throughput immunoaffinity based CTC isolation platform, the HBGO chip, was 
developed by incorporating a herringbone mixer into the GO Chip. To generate micro vortices to 
direct cells toward the bottom of the microchamber, twenty-four chevrons, two sets of twelve 
staggered asymmetrically, was defined as a single herringbone mixing unit and periodically 
shifted along the channel axis to place the vertex points with a spacing of 25 µm. The average 
cell capture efficiency for the unmodified GO Chip dramatically dropped to below 50% at 200 
µL/min, while the HBGO Chip maintained a target yield of > 80% up to 200 µL/min. The 
correlation between the channel length and flow rates at different capture efficiencies (60%, 70% 
and 80%) was further investigated. At the range of 50 ~ 200 µL/min, a strong linear relationship 
between flow rate and the required channel length to achieve a specific capture efficiency was 
observed.  
6.2 Limitations and Future Directions 
6.2.1 CTC isolation technologies 
In the past two decades, various CTC isolation platforms are developed based on the 
differences between tumor cells and surrounding blood cells such as varying expression patterns 
of membrane proteins or physical characteristics. Based on these different design principles, 
CTC isolation technologies can be categorized into immunoaffinity based isolation and physical 
properties based isolation [4]. The ultimate goal of CTC isolation is to capture CTC with (1) high 
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capture efficiency, (2) high purity of CTCs by removing surrounding blood cells, and (3) high 
throughput for handling large volumes of blood sample, and (4) the feasibility for downstream 
analysis [159].  
Immunoaffinity based technologies isolate CTCs using antibodies against cell surface 
markers that are expressed by tumor, but not by leukocytes. Anti-Epithelial cell adhesion 
molecule (EpCAM) is the mostly commonly used antibody as it is universally expressed in cells 
of solid tumors. The advantage of immunoaffinity based CTC isolation strategy is high purity of 
the isolated CTCs, which is important for downstream analysis, as contaminating leukocytes will 
affect the accuracy of the analysis [159]. Moreover, many immunoaffinity based platforms can 
process whole blood directly without any preprocessing process such as red blood cell lysis 
which may cause the loss of CTCs.  
However, immunoaffinity based isolation also have a few drawbacks. As CTCs may 
undergo EMT, in which the epithelial markers are down-regulated, isolation based on EpCAM 
may fail to capture this subgroup of CTCs. The GO Chip (used in Chapter 2 and Chapter 3), an 
immunoaffinity based approach, incorporates nanomaterial to achieve high antibody coating 
density of anti-EpCAM and thus enables the isolation of CTCs with low level of EpCAM 
expression [21]. Moreover, to capture additional CTCs subgroups, cocktails of antibodies (anti-
EpCAM, anti-CD133, and anti-EGFR for NSCLC; anti-EpCAM and anti-CD133 for pancreatic 
cancer) were incorporated in the GO chip.  
The GO chip shares another common drawback across most technologies with antibodies 
attached to a surface: the limitation of post-capture analysis because of the difficulty in releasing 
viable cells from the capture substrate. To overcome this problem, temperature-sensitive 
polymer-graphene oxide composite based chip was developed (Chapter 4). Over 90% capture 
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efficiency and release efficiency is achieved. Released CTCs were viable and structurally intact, 
enabling subsequent analysis such as standard clinical cytopathological and genetic testing. The 
polymer-GO nanocomposite films were prepared through drop-casting a DMF solution of 
polymer and functionalized GO. Drop-casting is a quick and easy method to generate thin films 
without wasting materials [160]. However, when using drop casting method, differences in 
evaporation rates across the substrate or concentration fluctuations can result in variations in film 
thickness and poor uniformity of the internal structure. In a series of experiments, we did 
observed high variations in the capture and release efficiency of tumor cells when different 
batches of polymer-GO composite were used. The robustness of the device may be improved by 
applying different solvents [161] or changing the deposition technique [162].  
Another major concern for microfluidic affinity-based devices is the low throughput, 
which limits the blood volume that could be processed. For instance, in the CTC-chip, when the 
flow rate increased from 1 to 3 mL/hr, the capture efficiency dropped drastically [10]. This is 
because of that under high flow rate, the shear force overcomes antibody-antigen affinity 
interactions [158], [159]. The GO chip currently processes blood sample at 1mL/hr. To reduce 
the processing time for high volume of blood (5 ~ 10 ml), we developed the HBGO chip by 
incorporating a herringbone mixer into the GO chip (Chapter 4). The herringbone structure 
generates micro vortices to direct cells to the substrate where the antibodies are tethered. By 
maximizing the cell-antibody collisions, over 90% capture efficiency is achieved at 200 µL/min 
(12 mL/hr). This device will be further tested with clinical samples from cancer patients to 
further validate its performance. 
6.2.2 Validation of the clinical utility of CTCs 
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In this thesis, serial blood samples from 26 locally advanced cancer patients and 12 
NSCLC patients were analyzed using the GO chips. While CTC counts and their molecular 
features are correlated with the progression free survival time of patients in this small patient 
cohort, these findings need further validation with a larger sample size in order to confirm the 
prognostic value of CTCs. Additionally, in this study with pancreatic cancer (Chapter 2), patients 
enrolled in the study are on different chemotherapy regimens, which may have distinct effects on 
the key regulators for drug resistance. Thus the molecular profiling of CTCs should be studied in 
a group of patients receiving the same treatment regimen to investigate the potential of CTCs for 
predicting treatment response [163]. Once the correlations are validated, the changes in CTC 
number and the molecular features of CTCs can be used to create a predictive model for 
treatment response and tumor progression and can be tested in an independent patient group.  
 In another study on NSCLC (Chapter 3), because we demonstrated the up-regulation of 
PD-L1 expression in CTCs during radiation or radiochemotherapy, we suggested that PD-L1 
expression in CTCs have the potential to act as a pharmacodynamic marker to guide the 
combination of anti- PD-1/PD-L1 therapies with radiation. When combination therapies are 
applied, treatment dose, fraction, timing and sequence need to be carefully planned and 
monitored to enhance, rather than compromise, the effectiveness of monotherapy [99]. Future 
efforts should incorporate dynamic monitoring of PD-L1 (+) CTCs in clinical trials with 
combined therapy for assessing the optimal timing and sequence. For instance, once the increase 
of PD-L1 (+) CTC number is observed, it may indicate tumor immune escape and can give the 
guidance as to the optimal time point to start immunotherapy 
6.2.3 Genetic analysis of CTCs 
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The extremely low prevalence of CTCs not only poses a challenge for CTC isolation, but 
also hinders the molecular analysis of CTCs. Genetic assays have traditionally been used to 
analyze tissue fragments or large number of cells.  RT-PCR has been used to detect tumor-
associated antigens in the peripheral blood and the sensitivity could be as high as one CTC per 
105 or 106 leukocytes [164] . However, the sensitivity of detection and accuracy varies, 
depending on the tumor type and the choice of genes of interest. In this thesis, CTCs were first 
isolated by the GO chip and then analyzed for mRNA profiling via a RT-PCR protocol suitable 
for detecting the expression of low-abundance mRNAs. 
 However, although the purity of CTCs isolated via the GO chip is much higher than via 
other conventional methods [21], the enriched cell population still contains a surplus of 
leukocytes. Therefore, the genetic analysis of CTCs may be masked by signals from the 
contaminating leukocytes and result in false negatives. To overcome this challenge, the single 
cell profiling of CTCs has been established for different genetic analysis methods such as 
transcriptome analysis and whole-genome sequencing [165], [166]. Moreover, single cell 
analysis can address the heterogeneity of CTCs, which may be shed from distinct subclones 
within the tumor or from primary and/or different metastatic sites.  The polymer-GO chip 
reported in Chapter 3 enables the release of CTCs after isolation, and the collected cell solution 
can be readily processed for single cell profiling using platforms such as C1 machine from 
Fluidigm.  
6.2.4 Developing an in-vivo CTC isolation system 
One major drawback of the existing immunoaffinity based CTC isolation technologies is 
the low throughput, which typically ranges from 1 ~ 3 ml blood per hour [159]. Because only a 
limited blood volume can be processed in practice, a low number of CTCs are captured, which 
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may not be sufficient for downstream analysis. Furthermore, the small number of CTCs may not 
accurately reflect the spectrum of tumor cell heterogeneity and may lead to statistical variability. 
In order to harvest a sufficient number of CTCs in peripheral blood, we envisioned developing 
an in-vivo CTC isolation system that can be worn on patients and continuously collect CTCs 
directly from the peripheral vein via a dual lumen catheter. Using this system, blood can be 
routed at a define flow rate (over 0.2 mL/min) through the CTC capture device for several hours, 
permitting the screening of large blood volumes for improved probability of detection and 
statistical accuracy of the analysis. One major challenge of building such system is the 
development of a CTC isolation device which achieves efficient cell capture at high flow rate. 
In chapter 4, we presented the HBGO chip, which is developed on the basis of the GO chip 
and achieved an over 10-fold increase in throughput. In addition to shortening the processing 
time of blood samples for in-vitro CTC isolation, the HBGO chip provides unique advantages to 
realize the in-vivo CTC isolation. The HBGO chip is a great fit for in-vivo CTC isolation for the 
following reasons: (1) it achieve high capture efficiency (>80%) at high flow rate (up to 200 
µL/hr); (2) it can process whole blood at a high flow rate without any preprocessing step or 
infusion of any solution; (3) the device has low chance of clogging; (4) the device is portable. 
Therefore, the HBGO chip can be incorporate into an indwelling catheter system for in-vivo CTC 
isolation. 
To achieve continuous blood sampling for CTC isolation, this system is designed to 
consist of a CTC capture module (the HBGO chip), peristaltic pump for continuous blood 
sampling from the peripheral vein through a dual-lumen catheter, a microcontroller to manage 
the flow rate, and a heparin injector to prevent blood clot formation during operation. Future 
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study will focus on the integration of the system and the safety of the cannulization and 
apheresis. This system could be tested in living vertebrate animal (such as experimental dogs).  
6.3 Concluding remarks 
This work highlights the clinical utility of CTCs as a potential biomarker to predict and 
monitor the treatment response and outcome in pancreatic cancer and NSCLC. The nanomaterial 
based microfluidic devices introduced here utilize various strategies to capture CTC with high 
sensitivity and can be applied in CTC studies for various cancer types. Ultimately, these studies 
hold the potential to help improve personalized therapy for cancer patients and identify 
promising therapeutic targets. 
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